Annual Reports

 
Quarterly Reports

  • 10-Q (Mar 2, 2018)
  • 10-Q (Dec 4, 2017)
  • 10-Q (Sep 1, 2017)
  • 10-Q (Mar 3, 2017)
  • 10-Q (Dec 5, 2016)
  • 10-Q (Sep 7, 2016)

 
8-K

 
Other

Medtronic 10-Q 2011

Table of Contents



 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

FORM 10-Q

 

x

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended October 28, 2011

 

Commission File Number 1-7707

 

(MEDTRONIC LOGO)

 

MEDTRONIC, INC.

(Exact name of registrant as specified in its charter)


 

 

 

Minnesota

 

41-0793183

(State of incorporation)

 

(I.R.S. Employer

 

 

Identification No.)

 

710 Medtronic Parkway

Minneapolis, Minnesota 55432

(Address of principal executive offices) (Zip Code)

 

(763) 514-4000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.      Yes   x     No   o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes   x     No   o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

 

 

Large accelerated filer x

 

Accelerated filer o

Non-accelerated filer o

 

Smaller Reporting Company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes   o     No   x

Shares of common stock, $.10 par value, outstanding on December 2, 2011: 1,055,341,156




TABLE OF CONTENTS

 

 

 

 

 

Item

 

Description

 

Page

 

 

 

 

 

PART I

1.

 

Financial Statements

 

1

2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

32

3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

50

4.

 

Controls and Procedures

 

50

PART II

1.

 

Legal Proceedings

 

51

1A.

 

Risk Factors

 

51

 

 

 

 

 

2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

51

6.

 

Exhibits

 

52



Table of Contents


PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

MEDTRONIC, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

Six months ended

 

 

 

October 28,
2011

 

October 29,
2010

 

October 28,
2011

 

October 29,
2010

 

 

 

(in millions, except per share data)

 

Net sales

 

$

4,132

 

$

3,903

 

$

8,181

 

$

7,677

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of products sold

 

 

1,014

 

 

961

 

 

2,020

 

 

1,855

 

Research and development expense

 

 

379

 

 

373

 

 

750

 

 

743

 

Selling, general, and administrative expense

 

 

1,437

 

 

1,371

 

 

2,845

 

 

2,705

 

Certain litigation charges, net

 

 

 

 

279

 

 

 

 

279

 

Acquisition-related items

 

 

(17

)

 

24

 

 

(4

)

 

39

 

Amortization of intangible assets

 

 

86

 

 

85

 

 

174

 

 

167

 

Other expense (income)

 

 

142

 

 

(9

)

 

251

 

 

(44

)

Interest expense, net

 

 

38

 

 

67

 

 

70

 

 

141

 

Total costs and expenses

 

 

3,079

 

 

3,151

 

 

6,106

 

 

5,885

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings before income taxes

 

 

1,053

 

 

752

 

 

2,075

 

 

1,792

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision for income taxes

 

 

182

 

 

186

 

 

383

 

 

396

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings

 

$

871

 

$

566

 

$

1,692

 

$

1,396

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings per share

 

$

0.82

 

$

0.52

 

$

1.60

 

$

1.29

 

Diluted earnings per share

 

$

0.82

 

$

0.52

 

$

1.59

 

$

1.28

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic weighted average shares outstanding

 

 

1,058.1

 

 

1,080.1

 

 

1,060.6

 

 

1,083.1

 

Diluted weighted average shares outstanding

 

 

1,063.1

 

 

1,083.7

 

 

1,066.2

 

 

1,086.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash dividends declared per common share

 

$

0.2425

 

$

0.2250

 

$

0.4850

 

$

0.4500

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

1


Table of Contents


MEDTRONIC, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

 

 

 

 

 

 

 

 

 

 

October 28,
2011

 

April 29,
2011

 

 

 

(in millions, except per share data)

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

1,048

 

$

1,382

 

Short-term investments

 

 

1,118

 

 

1,046

 

Accounts receivable, less allowances of $105 and $97, respectively

 

 

3,837

 

 

3,822

 

Inventories

 

 

1,840

 

 

1,695

 

Deferred tax assets, net

 

 

587

 

 

605

 

Prepaid expenses and other current assets

 

 

584

 

 

567

 

 

 

 

 

 

 

 

 

Total current assets

 

 

9,014

 

 

9,117

 

 

 

 

 

 

 

 

 

Property, plant, and equipment

 

 

6,065

 

 

5,817

 

Accumulated depreciation

 

 

(3,530

)

 

(3,306

)

Property, plant, and equipment, net

 

 

2,535

 

 

2,511

 

 

 

 

 

 

 

 

 

Goodwill

 

 

9,944

 

 

9,537

 

Other intangible assets, net

 

 

2,875

 

 

2,777

 

Long-term investments

 

 

7,013

 

 

6,120

 

Other assets

 

 

372

 

 

362

 

 

 

 

 

 

 

 

 

Total assets

 

$

31,753

 

$

30,424

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Short-term borrowings

 

$

2,050

 

$

1,723

 

Accounts payable

 

 

543

 

 

511

 

Accrued compensation

 

 

765

 

 

896

 

Accrued income taxes

 

 

83

 

 

50

 

Other accrued expenses

 

 

1,293

 

 

1,534

 

 

 

 

 

 

 

 

 

Total current liabilities

 

 

4,734

 

 

4,714

 

 

 

 

 

 

 

 

 

Long-term debt

 

 

8,222

 

 

8,112

 

Long-term accrued compensation and retirement benefits

 

 

505

 

 

480

 

Long-term accrued income taxes

 

 

841

 

 

496

 

Long-term deferred tax liabilities, net

 

 

293

 

 

220

 

Other long-term liabilities

 

 

419

 

 

434

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

15,014

 

 

14,456

 

 

 

 

 

 

 

 

 

Commitments and contingencies (Notes 3 and 19)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders’ equity:

 

 

 

 

 

 

 

Preferred stock— par value $1.00

 

 

 

 

 

Common stock— par value $0.10

 

 

106

 

 

107

 

Retained earnings

 

 

16,790

 

 

16,085

 

Accumulated other comprehensive loss

 

 

(157

)

 

(224

)

 

 

 

 

 

 

 

 

Total shareholders’ equity

 

 

16,739

 

 

15,968

 

 

 

 

 

 

 

 

 

Total liabilities and shareholders’ equity

 

$

31,753

 

$

30,424

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2


Table of Contents


MEDTRONIC, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

 

 

 

 

 

 

 

 

 

 

Six months ended

 

 

 

October 28,
2011

 

October 29,
2010

 

 

 

(in millions)

 

Operating Activities:

 

 

 

 

 

 

 

Net earnings

 

$

1,692

 

$

1,396

 

Adjustments to reconcile net earnings to net cash provided by operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

 

437

 

 

402

 

Amortization of discount on senior convertible notes

 

 

42

 

 

86

 

Acquisition-related items

 

 

17

 

 

15

 

Provision for doubtful accounts

 

 

32

 

 

18

 

Deferred income taxes

 

 

(58

)

 

(77

)

Stock-based compensation

 

 

90

 

 

104

 

Change in operating assets and liabilities, net of effect of acquisitions:

 

 

 

 

 

 

 

Accounts receivable, net

 

 

(119

)

 

(72

)

Inventories

 

 

(147

)

 

(108

)

Accounts payable and accrued liabilities

 

 

(354

)

 

(429

)

Other operating assets and liabilities

 

 

606

 

 

94

 

Certain litigation charges, net

 

 

 

 

279

 

Certain litigation payments

 

 

 

 

(5

)

 

 

 

 

 

 

 

 

Net cash provided by operating activities

 

 

2,238

 

 

1,703

 

 

 

 

 

 

 

 

 

Investing Activities:

 

 

 

 

 

 

 

Acquisitions, net of cash acquired

 

 

(617

)

 

(452

)

Purchase of intellectual property

 

 

(8

)

 

(17

)

Additions to property, plant, and equipment

 

 

(282

)

 

(258

)

Purchases of marketable securities

 

 

(3,866

)

 

(3,425

)

Sales and maturities of marketable securities

 

 

3,008

 

 

2,793

 

Other investing activities, net

 

 

9

 

 

(80

)

 

 

 

 

 

 

 

 

Net cash used in investing activities

 

 

(1,756

)

 

(1,439

)

 

 

 

 

 

 

 

 

Financing Activities:

 

 

 

 

 

 

 

Change in short-term borrowings, net

 

 

302

 

 

1,181

 

Payments on long-term debt

 

 

(15

)

 

(402

)

Dividends to shareholders

 

 

(514

)

 

(488

)

Issuance of common stock

 

 

45

 

 

42

 

Repurchase of common stock

 

 

(600

)

 

(760

)

 

 

 

 

 

 

 

 

Net cash used in financing activities

 

 

(782

)

 

(427

)

 

 

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

 

(34

)

 

19

 

 

 

 

 

 

 

 

 

Net change in cash and cash equivalents

 

 

(334

)

 

(144

)

 

 

 

 

 

 

 

 

Cash and cash equivalents at beginning of period

 

 

1,382

 

 

1,400

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

$

1,048

 

$

1,256

 

 

 

 

 

 

 

 

 

Supplemental Cash Flow Information

 

 

 

 

 

 

 

Cash paid for:

 

 

 

 

 

 

 

Income taxes

 

$

99

 

$

552

 

Interest

 

 

161

 

 

219

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

3


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 1 – Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Medtronic, Inc. and its subsidiaries (Medtronic or the Company) for the periods presented. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended April 29, 2011.

The Company’s fiscal years 2012, 2011, and 2010 will end or ended on April 27, 2012, April 29, 2011, and April 30, 2010, respectively.

Note 2 – New Accounting Pronouncements

In May 2011, the Financial Accounting Standards Board (FASB) updated the accounting guidance related to fair value measurements. The updated guidance results in a consistent definition of fair value and common requirements for measurement of, and disclosure about, fair value between U.S. GAAP and International Financial Reporting Standards (IFRS). The updated guidance is effective for the Company beginning in the fourth quarter of fiscal year 2012. The adoption of this accounting guidance will not have a material impact on the Company’s consolidated financial statements.

In June 2011, the FASB updated the disclosure requirements for comprehensive income. The updated guidance requires companies to disclose the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The updated guidance does not affect how earnings per share is calculated or presented. The updated guidance is effective for the Company retrospectively beginning in the first quarter of fiscal year 2013. Since the accounting guidance only impacts disclosure requirements, its adoption will not have a material impact on the Company’s consolidated financial statements.

In September 2011, the FASB updated the accounting guidance related to annual and interim goodwill impairment tests. The updated accounting guidance allows entities to first assess qualitative factors before performing a quantitative assessment of the fair value of a reporting unit. If it is determined on the basis of qualitative factors, that the fair value of the reporting unit is more-likely-than-not less than the carrying amount, the existing quantitative impairment test is required. Otherwise, no further impairment testing is required. The updated guidance is effective for the Company beginning in the first quarter of fiscal year 2013 with early adoption permitted under certain circumstances. The adoption of this accounting guidance will not have a material impact on the Company’s consolidated financial statements.

Note 3 – Acquisitions and Acquisition-Related Items

The Company had various acquisitions and other acquisition-related activity during the first two quarters of fiscal years 2012 and 2011. Certain acquisitions were accounted for as business combinations as noted below. In accordance with authoritative guidance on business combination accounting, the assets and liabilities of the company acquired were recorded as of the acquisition date, at their respective fair values, and consolidated with the Company. The purchase price allocation is based on estimates of the fair value of assets acquired and liabilities assumed. The pro forma impact of these acquisitions was not significant, individually or in the aggregate, to the results of the Company for the three and six months ended October 28, 2011 or October 29, 2010. The results of operations related to each company acquired have been included in the Company’s consolidated statements of earnings since the date each company was acquired.

Three and six months ended October 28, 2011

Salient Surgical Technologies, Inc.

On August 31, 2011, the Company acquired Salient Surgical Technologies, Inc. (Salient). Salient develops and markets devices for haemostatic sealing of soft tissue and bone incorporating advanced energy technology. Salient’s devices are used in a variety of surgical procedures including orthopedic surgery, spine, open abdominal, and thoracic procedures. Total consideration for the transaction was approximately $497 million. Medtronic had previously invested in Salient and held an 8.9 percent ownership position in the company. Net of this ownership position, the transaction value was approximately $452 million. Based upon the acquisition valuation, the Company acquired $162 million of technology-based intangible assets that had an estimated useful life of 12 years at the time of acquisition, $46 million of in-process research and development (IPR&D), $53 million of net tangible liabilities, and $342 million of goodwill. The value attributable to IPR&D has been capitalized as an indefinite-lived intangible asset. The IPR&D primarily relates to the future launch of Salient’s concentric wire product. Acquired goodwill is not deductible for tax purposes.

4


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

The Company accounted for the acquisition of Salient as a business combination. The Company recorded the identifiable assets acquired and liabilities assumed at fair values on the acquisition date as follows:

 

 

 

 

 

(in millions)

 

 

 

 

Current assets

 

$

20

 

Property, plant, and equipment

 

 

11

 

IPR&D

 

 

46

 

Other intangible assets

 

 

162

 

Goodwill

 

 

342

 

Other assets

 

 

1

 

Total assets acquired

 

 

582

 

 

 

 

 

 

Current liabilities

 

 

43

 

Long-term deferred tax liabilities, net

 

 

42

 

Total liabilities assumed

 

 

85

 

Net assets acquired

 

$

497

 

PEAK Surgical, Inc.

On August 31, 2011, the Company acquired PEAK Surgical, Inc. (PEAK). PEAK develops and markets tissue dissection devices incorporating advanced energy technology. Total consideration for the transaction was approximately $113 million. Medtronic had previously invested in PEAK and held an 18.9 percent ownership position in the company. Net of this ownership position, the transaction value was approximately $96 million. Based upon the acquisition valuation, the Company acquired $74 million of technology-based intangible assets that had an estimated useful life of 12 years at the time of acquisition, $17 million of net tangible liabilities, and $56 million of goodwill. Acquired goodwill is not deductible for tax purposes.

The Company accounted for the acquisition of PEAK as a business combination. The Company recorded the identifiable assets acquired and liabilities assumed at fair values on the acquisition date as follows:

 

 

 

 

 

(in millions)

 

 

 

 

Current assets

 

$

5

 

Property, plant, and equipment

 

 

5

 

Other intangible assets

 

 

74

 

Goodwill

 

 

56

 

Total assets acquired

 

 

140

 

 

 

 

 

 

Current liabilities

 

 

10

 

Long-term deferred tax liabilities, net

 

 

17

 

Total liabilities assumed

 

 

27

 

Net assets acquired

 

$

113

 

Other Acquisitions and Acquisition-Related Items

During the three and six months ended October 28, 2011, the Company recorded a net gain from acquisition-related items of $17 million and $4 million, respectively. In connection with the acquisitions of Salient and PEAK, the Company recognized gains of $32 million and $6 million, respectively, during the three months ended October 28, 2011 on its previously held investments. In connection with these acquisitions, the Company began to assess and formulate a plan for the elimination of duplicative positions and the termination of certain contractual obligations. As a result, the Company incurred approximately $5 million of certain acquisition-related costs, which include legal fees, severance costs, change in control costs, and contract termination costs. Additionally, during the three and six months ended October 28, 2011 the Company recorded charges of $9 million and $17 million, respectively, related to the change in fair value of contingent milestone payments associated with acquisitions subsequent to April 29, 2009 and transaction costs of $7 million and $12 million, respectively, related to the pending divestiture of the Physio-Control business. These amounts are included within acquisition-related items in the condensed consolidated statement of earnings.

5


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Three and six months ended October 29, 2010

ATS Medical, Inc.

On August 12, 2010, the Company acquired ATS Medical, Inc. (ATS Medical). ATS Medical is a leading developer, manufacturer, and marketer of products and services focused on cardiac surgery, including heart valves and surgical cryoablation technology. Under the terms of the agreement, ATS Medical shareholders received $4.00 per share in cash for each share of ATS Medical common stock that they owned. Total consideration for the transaction was $394 million which includes $30 million of ATS Medical debt and acquired contingent consideration of $10 million. In connection with the acquisition, the Company acquired $101 million of technology-based intangible assets that had an estimated useful life of 11 years at the time of acquisition, $6 million of IPR&D, $78 million of net tangible assets, and $209 million of goodwill. The value attributable to IPR&D, which relates to the future launch of ATS Medical’s next generation surgical ablation and 3f tissue valve products, has been capitalized as an indefinite-lived intangible asset. The goodwill is not deductible for tax purposes.

The Company accounted for the acquisition of ATS Medical as a business combination. The Company recorded the identifiable assets acquired and liabilities assumed at fair values on the acquisition date as follows:

 

 

 

 

 

(in millions)

 

 

 

 

Current assets

 

$

51

 

Property, plant, and equipment

 

 

7

 

IPR&D

 

 

6

 

Other intangible assets

 

 

101

 

Goodwill

 

 

209

 

Long-term deferred tax assets, net

 

 

34

 

Total assets acquired

 

 

408

 

 

 

 

 

 

Current liabilities

 

 

14

 

Total liabilities assumed

 

 

14

 

Net assets acquired

 

$

394

 

Axon Surgical

On June 2, 2010, the Company acquired substantially all of the assets of Axon Surgical (Axon), a privately-held company. Prior to the acquisition, the Company distributed a large portion of Axon’s products. The agreement will allow the Company to bring to market the next generation of surgeon-directed and professionally supported spinal neuromonitoring technology and expand the availability of this technology. Total consideration for the transaction, net of cash acquired, was $62 million, which includes the settlement of existing Axon debt. In connection with the acquisition of Axon, the Company acquired $41 million of technology-based intangible assets that had an estimated useful life of 10 years at the time of acquisition, $5 million of tangible assets, and $16 million of goodwill. The goodwill is deductible for tax purposes. The Company accounted for the acquisition of Axon as a business combination.

Other Acquisitions and Acquisition-Related Items

On September 14, 2010, the Company acquired a developer of vascular suturing products used in connection with cardiovascular and vascular procedures that require a puncture or incision to the artery. The terms of the transaction included an upfront payment of $15 million and additional payments of up to $10 million contingent upon achievement of certain milestones. Total consideration for the transaction was valued at approximately $21 million, which includes the estimated fair value of additional milestone-based contingent consideration of $6 million. The Company accounted for this acquisition as a business combination.

6


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

During the six months ended October 29, 2010, the Company incurred a $15 million IPR&D charge related to a milestone payment under the existing terms of a royalty bearing, non-exclusive patent cross-licensing agreement with NeuroPace, Inc. Product commercialization related to this technology had not yet been achieved. As a result, in accordance with authoritative guidance, the payments for these transactions were immediately expensed as IPR&D since technological feasibility had not yet been reached and such technology has no future alternative use. This amount was recorded within acquisition-related items in the condensed consolidated statement of earnings.

In connection with the ATS Medical acquisition, the Company began to assess and formulate a plan for the elimination of duplicative positions and the termination of certain contractual obligations. As a result, during the three and six months ended October 29, 2010 the Company incurred approximately $24 million of certain acquisition-related costs, which include acquisition-related legal fees and severance costs, change in control costs, and contract termination costs which were recorded within acquisition-related items in the condensed consolidated statement of earnings.

Contingent Consideration

Certain of the Company’s business combinations or purchases of intellectual property involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones and/or various other favorable operating conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels, achieving product development targets, or obtaining regulatory approvals. As a result of the Company adopting new authoritative guidance in fiscal year 2010 related to business combinations, contingent consideration is recorded at the estimated fair value of the contingent milestone payment on the acquisition date for all acquisitions subsequent to April 24, 2009. The fair value of the contingent milestone consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within acquisition-related items in the condensed consolidated statements of earnings. The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. See Note 7 for further information regarding fair value measurements.

At October 28, 2011, the estimated maximum potential amount of undiscounted future contingent consideration that the Company is expected to make associated with all completed business combinations or purchases of intellectual property prior to April 24, 2009 was approximately $235 million. The milestones associated with the contingent consideration must be reached in future periods ranging from fiscal years 2012 to 2016 in order for the consideration to be paid.

The fair value of contingent milestone payments associated with acquisitions subsequent to April 24, 2009 was remeasured as of October 28, 2011 and April 29, 2011 at $288 million and $335 million, respectively. As of October 28, 2011, $263 million was reflected in other long-term liabilities and $25 million was reflected in other accrued expenses in the condensed consolidated balance sheet. As of October 29, 2010, $269 million was reflected in other long-term liabilities and $66 million was reflected in other accrued expenses in the condensed consolidated balance sheet. The following table provides a reconciliation of the beginning and ending balances of contingent milestone payments associated with acquisitions subsequent to April 24, 2009 measured at fair value that used significant unobservable inputs (Level 3):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

Six months ended

 

(in millions)

 

October 28, 2011

 

October 29, 2010

 

October 28, 2011

 

October 29, 2010

 

Beginning Balance

 

$

343

 

$

120

 

$

335

 

$

118

 

Purchase price contingent consideration

 

 

2

 

 

16

 

 

2

 

 

16

 

Contingent milestone payments

 

 

(66

)

 

 

 

(66

)

 

 

Change in fair value of contingent consideration

 

 

9

 

 

 

 

17

 

 

2

 

Ending Balance

 

$

288

 

$

136

 

$

288

 

$

136

 

Note 4 – Certain Litigation Charges, Net

The Company classifies material litigation reserves and gains recognized as certain litigation charges, net. During the three and six months ended October 28, 2011, there were no certain litigation charges, net.

During the three months ended October 29, 2010, the Company recorded certain litigation charges, net of $279 million related primarily to a settlement involving the Sprint Fidelis family of defibrillation leads and an accounting charge for Other Matters litigation. The Sprint Fidelis settlement related to the resolution of certain outstanding product liability litigation related to the Sprint Fidelis family of defibrillation leads that were subject to a field action announced October 15, 2007. The parties subsequently reached an adjusted settlement agreement to pay a total of $221 million to resolve over 14,000 filed and unfiled claims. See Note 19 for additional information.

During the first quarter of fiscal year 2011, there were no certain litigation charges, net.

7


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 5 – Restructuring Charges

During the three and six months ended October 28, 2011, the Company did not incur any restructuring charges.

Fiscal Year 2011 Initiative

In the fourth quarter of fiscal year 2011, the Company recorded a $272 million restructuring charge, which consisted of employee termination costs of $177 million, asset write-downs of $24 million, contract termination fees of $45 million, and other related costs of $26 million. The fiscal year 2011 initiative was designed to restructure the business to align its cost structure to current market conditions and to continue to position the Company for long-term sustainable growth in emerging markets and new technologies. Included in the $177 million of employee termination costs were severance and the associated costs of continued medical benefits and outplacement services, as well as $15 million of incremental defined benefit pension and post-retirement related expenses for employees that accepted voluntary early retirement packages. These costs are not included in the table summarizing the restructuring costs below because they are associated with costs that are accounted for under the pension and post-retirement rules. For further discussion on the incremental defined benefit pension and post-retirement related expenses, see Note 14 of the Company’s Annual Report on Form 10-K for the year ended April 29, 2011. Of the $24 million of asset write-downs, $11 million related to inventory write-offs of discontinued product lines and production-related asset impairments, and therefore, was recorded within cost of products sold in the consolidated statement of earnings. Additionally, included in the other related costs was a $19 million intangible asset impairment related to the discontinuance of a product line within the CardioVascular business.

In connection with the fiscal year 2011 initiative, as of the end of the fourth quarter of fiscal year 2011, the Company had identified approximately 2,100 net positions for elimination to be achieved through voluntary early retirement packages offered to employees, voluntary separation, and involuntary separation. Of the 2,100 net positions identified, approximately 1,700 positions have been eliminated as of October 28, 2011. The fiscal year 2011 initiative is scheduled to be substantially complete by the end of the fourth quarter of fiscal year 2012.

A summary of the activity related to the fiscal year 2011 initiative is presented below:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fiscal Year 2011 Initiative

 

(in millions)

 

Employee
Termination
Costs

 

Asset
Write-downs

 

Other
Costs

 

Total

 

Balance as of April 30, 2010

 

$

 

$

 

$

 

$

 

Restructuring charges

 

 

162

 

 

24

 

 

71

 

 

257

 

Payments/write-downs

 

 

(5

)

 

(24

)

 

(24

)

 

(53

)

Balance as of April 29, 2011

 

$

157

 

$

 

$

47

 

$

204

 

Payments/write-downs

 

 

(63

)

 

 

 

(13

)

 

(76

)

Balance as of July 29, 2011

 

$

94

 

$

 

$

34

 

$

128

 

Payments/write-downs

 

 

(43

)

 

 

 

(15

)

 

(58

)

Balance as of October 28, 2011

 

$

51

 

$

 

$

19

 

$

70

 

8


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 6 – Investments

The Company holds short-term and long-term investments, which consist primarily of marketable debt and equity securities.

Information regarding the Company’s short-term and long-term investments at October 28, 2011 is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

Cost

 

Unrealized
Gains

 

Unrealized
Losses

 

Fair Value

 

Available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

2,512

 

$

24

 

$

(13

)

$

2,523

 

Auction rate securities

 

 

167

 

 

 

 

(40

)

 

127

 

Mortgage-backed securities

 

 

933

 

 

10

 

 

(12

)

 

931

 

U.S. government and agency securities

 

 

2,842

 

 

45

 

 

(2

)

 

2,885

 

Foreign government and agency securities

 

 

90

 

 

1

 

 

 

 

91

 

Certificates of deposit

 

 

97

 

 

 

 

 

 

97

 

Other asset-backed securities

 

 

437

 

 

2

 

 

(1

)

 

438

 

Marketable equity securities

 

 

79

 

 

111

 

 

(26

)

 

164

 

Trading securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

Exchange-traded funds

 

 

45

 

 

1

 

 

(2

)

 

44

 

Cost method, equity method, and other investments

 

 

831

 

 

 

 

 

 

831

 

Total short-term and long-term investments

 

$

8,033

 

$

194

 

$

(96

)

$

8,131

 

Information regarding the Company’s short-term and long-term investments at April 29, 2011 is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

Cost

 

Unrealized
Gains

 

Unrealized
Losses

 

Fair Value

 

Available-for-sale securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

1,947

 

$

20

 

$

(6

)

$

1,961

 

Auction rate securities

 

 

167

 

 

 

 

(34

)

 

133

 

Mortgage-backed securities

 

 

783

 

 

10

 

 

(8

)

 

785

 

U.S. government and agency securities

 

 

2,731

 

 

26

 

 

(1

)

 

2,756

 

Foreign government and agency securities

 

 

130

 

 

1

 

 

 

 

131

 

Certificates of deposit

 

 

119

 

 

 

 

 

 

119

 

Other asset-backed securities

 

 

351

 

 

1

 

 

(3

)

 

349

 

Marketable equity securities

 

 

73

 

 

164

 

 

 

 

237

 

Trading securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

Exchange-traded funds

 

 

33

 

 

6

 

 

 

 

39

 

Cost method, equity method, and other investments

 

 

656

 

 

 

 

 

 

656

 

Total short-term and long-term investments

 

$

6,990

 

$

228

 

$

(52

)

$

7,166

 

Information regarding the Company’s available-for-sale and trading securities at October 28, 2011 and April 29, 2011 is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

October 28, 2011

 

April 29, 2011

 

(in millions)

 

Short-term

 

Long-term

 

Short-term

 

Long-term

 

Available-for-sale securities

 

$

1,118

 

$

6,138

 

$

1,046

 

$

5,425

 

Trading securities

 

 

 

 

44

 

 

 

 

39

 

Total

 

$

1,118

 

$

6,182

 

$

1,046

 

$

5,464

 

9


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

The following tables show the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary for less than 12 months and for more than 12 months, aggregated by investment category as of October 28, 2011 and April 29, 2011:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

October 28, 2011

 

 

 

Less than 12 months

 

More than 12 months

 

(in millions)

 

Fair Value

 

Unrealized
Losses

 

Fair Value

 

Unrealized
Losses

 

Corporate debt securities

 

$

793

 

$

(10

)

$

10

 

$

(3

)

Auction rate securities

 

 

 

 

 

 

127

 

 

(40

)

Mortgage-backed securities

 

 

308

 

 

(3

)

 

62

 

 

(9

)

U.S. government and agency securities

 

 

679

 

 

(2

)

 

 

 

 

Other asset-backed securities

 

 

 

 

 

 

16

 

 

(1

)

Marketable equity securities

 

 

53

 

 

(26

)

 

 

 

 

Total

 

$

1,833

 

$

(41

)

$

215

 

$

(53

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

April 29, 2011

 

 

 

Less than 12 months

 

More than 12 months

 

(in millions)

 

Fair Value

 

Unrealized
Losses

 

Fair Value

 

Unrealized
Losses

 

Corporate debt securities

 

$

256

 

$

(1

)

$

16

 

$

(5

)

Auction rate securities

 

 

 

 

 

 

133

 

 

(34

)

Mortgage-backed securities

 

 

161

 

 

(1

)

 

67

 

 

(7

)

U.S. government and agency securities

 

 

267

 

 

(1

)

 

 

 

 

Other asset-backed securities

 

 

74

 

 

(1

)

 

12

 

 

(2

)

Total

 

$

758

 

$

(4

)

$

228

 

$

(48

)

At October 28, 2011 the Company concluded that the unrealized losses associated with the available-for-sale securities detailed above were not other-than-temporary as the Company does not have the intent to sell, nor is it more likely than not that the Company will be required to sell, before recovery of the amortized cost.

Activity related to the Company’s short-term and long-term investment portfolio is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

 

October 28, 2011

 

October 29, 2010

 

(in millions)

 

Debt (a)

 

Equity (b)(c)

 

Debt (a)

 

Equity (b)

 

Proceeds from sales

 

$

1,406

 

$

12

 

$

1,609

 

$

 

Gross realized gains

 

 

14

 

 

50

 

 

10

 

 

 

Gross realized losses

 

 

(5

)

 

 

 

(3

)

 

 

Impairment losses recognized

 

 

 

 

(4

)

 

(2

)

 

(2

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six months ended

 

 

 

October 28, 2011

 

October 29, 2010

 

(in millions)

 

Debt (a)

 

Equity (b)(c)

 

Debt (a)

 

Equity (b)

 

Proceeds from sales

 

$

2,967

 

$

53

 

$

2,793

 

$

 

Gross realized gains

 

 

24

 

 

55

 

 

17

 

 

 

Gross realized losses

 

 

(7

)

 

 

 

(7

)

 

 

Impairment losses recognized

 

 

(1

)

 

(4

)

 

(5

)

 

(5

)


(a) Includes available-for-sale debt securities.
(b) Includes marketable equity securities, cost method, equity method, exchange-traded funds, and other investments.
(c) As a result of the Salient and PEAK acquisitions, the Company recognized a non-cash gain of $38 million during the three months ended October 28, 2011 on its previously held minority investments.

The total other-than-temporary impairment losses on available-for-sale debt securities for the three and six months ended October 28, 2011 were $1 million and $3 million, respectively, of which $1 million and $2 million, respectively, were recognized in other comprehensive income resulting in less than $1 million and $1 million, respectively, of charges being recognized in earnings. The total other-than-temporary impairment losses on available-for-sale debt securities for the three and six months ended October 29, 2010 were $8 million and $17 million, respectively, of which $6 million and $12 million, respectively, were recognized in other comprehensive income resulting in $2 million and $5 million, respectively, of charges being recognized in earnings. These charges relate to credit losses on certain mortgage-backed securities and other asset-backed securities. The amount of credit losses represents the difference between the present value of cash flows expected to be collected on these securities and the amortized cost. Based on the Company’s assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which it invested, the Company believes it has recorded all necessary other-than-temporary impairments as the Company does not have the intent to sell, nor is it more likely than not that the Company will be required to sell, before recovery of the amortized cost.

10


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

The following table shows the credit loss portion of other-than-temporary impairments on debt securities held by the Company as of the dates indicated and the corresponding changes in such amounts:

 

 

 

 

 

 

 

 

 

 

Three months ended

 

(in millions)

 

October 28, 2011

 

October 29, 2010

 

Beginning Balance

 

$

20

 

 

19

 

Additional credit losses recognized on securities previously impaired

 

 

 

 

1

 

Credit losses recognized on securities previously not impaired

 

 

 

 

1

 

Ending Balance

 

$

20

 

$

21

 

 

 

 

 

 

 

 

 

 

 

Six months ended

 

(in millions)

 

October 28, 2011

 

October 29, 2010

 

Beginning Balance

 

$

20

 

 

17

 

Additional credit losses recognized on securities previously impaired

 

 

 

 

3

 

Credit losses recognized on securities previously not impaired

 

 

1

 

 

2

 

Reductions for securities sold during the period

 

 

(1

)

 

(1

)

Ending Balance

 

$

20

 

$

21

 

The October 28, 2011 balance of available-for-sale debt securities by contractual maturity is shown in the following table at fair value. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows, assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

 

 

 

 

 

(in millions)

 

October 28,
2011 

 

Due in one year or less

 

$

1,333

 

Due after one year through five years

 

 

4,936

 

Due after five years through ten years

 

 

669

 

Due after ten years

 

 

154

 

Total debt securities

 

$

7,092

 

As of October 28, 2011 and April 29, 2011, the aggregate carrying amount of equity and other securities without a quoted market price and accounted for using the cost or equity method was $831 million and $656 million, respectively. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment. The October 28, 2011 cost method, equity method, and other investments balance includes $464 million of investments in a public company which have trading restrictions through December 31, 2013. These investments will be reclassified to available-for-sale marketable equity securities when the restriction is within one year of lapsing.

Gains and losses realized on trading securities and available-for-sale debt securities are recorded in interest expense, net in the condensed consolidated statements of earnings. Gains and losses realized on marketable equity securities, cost method, equity method, and other investments are recorded in other expense (income) in the condensed consolidated statements of earnings. In addition, unrealized gains and losses on available-for-sale debt securities are recorded in accumulated other comprehensive loss in the condensed consolidated balance sheets and unrealized gains and losses on trading securities are recorded in interest expense, net in the condensed consolidated statements of earnings. Gains and losses from the sale of investments are calculated based on the specific identification method.

11


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 7 – Fair Value Measurements

The Company follows the authoritative guidance on fair value measurements and disclosures, with respect to assets and liabilities that are measured at fair value on both a recurring and nonrecurring basis. Under this guidance, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The hierarchy is broken down into three levels. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). Descriptions of the three levels of the fair value hierarchy are discussed in Note 6 of the Company’s Annual Report on Form 10-K for the year ended April 29, 2011.

See the section below titled Valuation Techniques for further discussion of how the Company determines fair value for financial assets and liabilities.

Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis

The authoritative guidance is principally applied to financial assets and liabilities such as marketable debt and equity securities that are classified and accounted for as trading, available-for-sale, and derivative instruments. Derivatives include cash flow hedges, freestanding derivative forward contracts, and interest rate swaps. These items are marked-to-market at each reporting period. The information in the following paragraphs and tables primarily addresses matters relative to these financial assets and liabilities.

The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value
as of
October 28, 2011

 

Fair Value Measurements
Using Inputs Considered as

 

(in millions)

 

 

Level 1

 

Level 2

 

Level 3

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

2,523

 

$

 

$

2,513

 

$

10

 

Auction rate securities

 

 

127

 

 

 

 

 

 

127

 

Mortgage-backed securities

 

 

931

 

 

 

 

900

 

 

31

 

U.S. government and agency securities

 

 

2,885

 

 

1,556

 

 

1,329

 

 

 

Foreign government and agency securities

 

 

91

 

 

 

 

91

 

 

 

Certificates of deposit

 

 

97

 

 

 

 

97

 

 

 

Other asset-backed securities

 

 

438

 

 

 

 

432

 

 

6

 

Marketable equity securities

 

 

164

 

 

164

 

 

 

 

 

Exchange-traded funds

 

 

44

 

 

44

 

 

 

 

 

Derivative assets

 

 

177

 

 

41

 

 

136

 

 

 

Total assets

 

$

7,477

 

$

1,805

 

$

5,498

 

$

174

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative liabilities

 

$

190

 

$

180

 

$

10

 

$

 

Total liabilities

 

$

190

 

$

180

 

$

10

 

$

 

12


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value
as of
April 29, 2011

 

Fair Value Measurements
Using Inputs Considered as

 

(in millions)

 

 

Level 1

 

Level 2

 

Level 3

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

$

1,961

 

$

 

$

1,944

 

$

17

 

Auction rate securities

 

 

133

 

 

 

 

 

 

133

 

Mortgage-backed securities

 

 

785

 

 

 

 

750

 

 

35

 

U.S. government and agency securities

 

 

2,756

 

 

1,453

 

 

1,303

 

 

 

Foreign government and agency securities

 

 

131

 

 

 

 

131

 

 

 

Certificates of deposit

 

 

119

 

 

 

 

119

 

 

 

Other asset-backed securities

 

 

349

 

 

 

 

343

 

 

6

 

Marketable equity securities

 

 

237

 

 

237

 

 

 

 

 

Exchange-traded funds

 

 

39

 

 

39

 

 

 

 

 

Derivative assets

 

 

130

 

 

21

 

 

109

 

 

 

Total assets

 

$

6,640

 

$

1,750

 

$

4,699

 

$

191

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative liabilities

 

$

303

 

$

303

 

$

 

$

 

Total liabilities

 

$

303

 

$

303

 

$

 

$

 

Valuation Techniques

Financial assets that are classified as Level 1 securities include highly liquid government bonds within the U.S. government and agency securities, marketable equity securities, and exchange-traded funds for which quoted market prices are available. In addition, the Company has determined that foreign currency forward contracts will be included in Level 1 as these are valued using quoted market prices in active markets which have identical assets or liabilities.

The valuation for most fixed maturity securities are classified as Level 2. Financial assets that are classified as Level 2 include corporate debt securities, U.S. government and agency securities, foreign government and agency securities, certificates of deposit, other asset-backed securities, and certain mortgage-backed securities whose value is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, interest rate swaps are included in Level 2 as the Company uses inputs other than quoted prices that are observable for the asset. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis.

Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Level 3 financial assets also include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation. Level 3 investment securities primarily include certain corporate debt securities, auction rate securities, certain mortgage-backed securities, and certain other asset-backed securities for which there was a decrease in the observability of market pricing for these investments. At October 28, 2011, these securities were valued primarily using broker pricing models that incorporate transaction details such as contractual terms, maturity, timing, and amount of expected future cash flows, as well as assumptions about liquidity and credit valuation adjustments of marketplace participants. The Company uses level 3 inputs in the measurement of contingent milestone payments and related liabilities for all acquisitions subsequent to April 24, 2009. See Note 3 for further information regarding contingent consideration.

The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no significant transfers between Level 1, Level 2, or Level 3 during the three or six months ended October 28, 2011 or October 29, 2010. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. The following tables provide a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that used significant unobservable inputs (Level 3) for the three and six months ended October 28, 2011 and October 29, 2010:

13


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended October 28, 2011

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

Total Level 3
Investments

 

Corporate debt
securities

 

Auction rate
securities

 

Mortgage-backed
securities

 

Other asset-
backed securities

 

Balance as of July 29, 2011

 

$

190

 

$

17

 

$

134

 

$

33

 

$

6

 

Total realized losses and other-than-temporary impairment losses included in earnings

 

 

(1

)

 

(1

)

 

 

 

 

 

 

Total unrealized gains/(losses) included in other comprehensive income

 

 

(7

)

 

1

 

 

(7

)

 

(1

)

 

 

Settlements

 

 

(8

)

 

(7

)

 

 

 

(1

)

 

 

Balance as of October 28, 2011

 

$

174

 

$

10

 

$

127

 

$

31

 

$

6

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended October 29, 2010

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

Total Level 3 Investments

 

Corporate debt
securities

 

Auction rate
securities

 

Mortgage-backed
securities

 

Other asset-
backed securities

 

Balance as of July 30, 2010

 

$

198

 

$

16

 

$

138

 

$

37

 

$

7

 

Total realized losses and other-than-temporary impairment losses included in earnings

 

 

(2

)

 

(1

)

 

 

 

(1

)

 

 

Total unrealized gains/(losses) included in other comprehensive income

 

 

9

 

 

2

 

 

5

 

 

2

 

 

 

Settlements

 

 

(3

)

 

 

 

 

 

(2

)

 

(1

)

Balance as of October 29, 2010

 

$

202

 

$

17

 

$

143

 

$

36

 

$

6

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six months ended October 28, 2011

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

Total Level 3
Investments

 

Corporate debt
securities

 

Auction rate
securities

 

Mortgage-
backed securities

 

Other asset-
backed securities

 

Balance as of April 29, 2011

 

$

191

 

$

17

 

$

133

 

$

35

 

$

6

 

Total realized losses and other-than-temporary impairment losses included in earnings

 

 

(2

)

 

(1

)

 

 

 

 

 

(1

)

Total unrealized gains/(losses) included in other comprehensive income

 

 

(5

)

 

1

 

 

(6

)

 

(1

)

 

1

 

Settlements

 

 

(10

)

 

(7

)

 

 

 

(3

)

 

 

Balance as of October 28, 2011

 

$

174

 

$

10

 

$

127

 

$

31

 

$

6

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six months ended October 29, 2010

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

Total Level 3
Investments

 

Corporate debt
securities

 

Auction rate
securities

 

Mortgage-
backed securities

 

Other asset-
backed securities

 

Balance as of April 30, 2010

 

$

213

 

$

16

 

$

142

 

$

39

 

$

16

 

Total realized losses and other-than-temporary impairment losses included in earnings

 

 

(4

)

 

(2

)

 

 

 

(2

)

 

 

Total unrealized gains/(losses) included in other comprehensive income

 

 

7

 

 

4

 

 

1

 

 

2

 

 

 

Settlements

 

 

(14

)

 

(1

)

 

 

 

(3

)

 

(10

)

Balance as of October 29, 2010

 

$

202

 

$

17

 

$

143

 

$

36

 

$

6

 

Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis

Non-financial assets such as equity and other securities that are accounted for using the cost or equity method, goodwill, intangible assets, and property, plant, and equipment are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment is recognized.

14


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

The Company holds investments in equity and other securities that are accounted for using the cost or equity method, which are classified as long-term investments in the condensed consolidated balance sheets. The aggregate carrying amount of these investments was $831 million as of October 28, 2011 and $656 million as of April 29, 2011. These cost or equity method investments are measured at fair value on a nonrecurring basis. The fair value of the Company’s cost or equity method investments is not estimated if there are no identified events or changes in circumstance that may have a significant adverse effect on the fair value of these investments. During the three and six months ended October 28, 2011 and October 29, 2010, the Company determined that the fair values of certain cost method investments were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $4 million in impairment charges during the three and six months ended October 28, 2011, and $2 million and $5 million in impairment charges during the three and six months ended October 29, 2010, respectively. The impairment charges related to the cost method investments were recorded in other expense (income) in the condensed consolidated statements of earnings. These investments fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value, as the investments are privately held entities without quoted market prices. To determine the fair value of these investments, the Company used all pertinent financial information that was available related to the entities, including financial statements and market participant valuations from recent and proposed equity offerings.

The Company assesses the impairment of intangible assets whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. The aggregate carrying amount of intangible assets was $2.875 billion as of October 28, 2011 and $2.777 billion as of April 29, 2011, respectively. These assets are measured at fair value on a nonrecurring basis. The fair value of the Company’s intangible assets is not estimated if there is no change in events or circumstances that indicate the carrying amount of an intangible asset may not be recoverable. The Company did not record any intangible asset impairments during the three and six months ended October 28, 2011 or October 29, 2010.

The Company assesses the impairment of goodwill annually or whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The aggregate carrying amount of goodwill was $9.944 billion as of October 28, 2011 and $9.537 billion as of April 29, 2011, respectively. These assets are measured at fair value on a nonrecurring basis. The fair value of the Company’s goodwill is not estimated if there is no change in events or circumstances that indicate the carrying amount may be impaired. The Company did not record any goodwill impairments during the three and six months ended October 28, 2011 or October 29, 2010.

The Company assesses the impairment of property, plant, and equipment whenever events or changes in circumstances indicate that the carrying amount of a property, plant, and equipment asset may not be recoverable. The Company did not recognize any significant impairments of property, plant, and equipment during the three and six months ended October 28, 2011 or October 29, 2010.

Financial Instruments Not Measured at Fair Value

The estimated fair value of the Company’s long-term debt, including the short-term portion, as of October 28, 2011 was $8.784 billion compared to a principal value of $8.078 billion, and as of April 29, 2011 was $8.524 billion compared to a principal value of $8.096 billion. Fair value was estimated using quoted market prices for the same or similar instruments. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts, and derivative/hedging activity.

Note 8 – Financing Arrangements

Senior Convertible Notes

In April 2006, the Company issued $2.200 billion of 1.500 percent Senior Convertible Notes due 2011 (2011 Senior Convertible Notes) and $2.200 billion of 1.625 percent Senior Convertible Notes due 2013 (2013 Senior Convertible Notes) (collectively, the Senior Convertible Notes). The Senior Convertible Notes were issued at par and pay interest in cash semi-annually in arrears on April 15 and October 15 of each year. The 2011 Senior Convertible Notes were repaid in April 2011. The 2013 Senior Convertible Notes are unsecured unsubordinated obligations and rank equally with all other unsecured and unsubordinated indebtedness.

Concurrent with the issuance of the Senior Convertible Notes, the Company purchased call options on its common stock in private transactions. The call options allow the Company to receive shares of the Company’s common stock and/or cash from counterparties equal to the amounts of common stock and/or cash related to the excess conversion value that it would pay to the holders of the 2013 Senior Convertible Notes upon conversion.

In separate transactions, the Company sold warrants to issue shares of the Company’s common stock at an exercise price of $76.56 per share in private transactions. Pursuant to these transactions, warrants for 41 million shares of the Company’s common stock may be settled over a specified period beginning in July 2011 and warrants for 41 million shares of the Company’s common stock may be settled over a specified period beginning in July 2013. As of October 28, 2011, warrants for 31 million shares of the Company’s common stock expired.

15


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Under the authoritative guidance, the Company concluded that the purchased call options and sold warrants were indexed to its own stock and should continue to be classified in shareholders’ equity and not be separated as a derivative.

Authoritative guidance provides that contracts are initially classified as equity if (1) the contract requires physical settlement or net-share settlement, or (2) the contract gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The settlement terms of the Company’s purchased call options and sold warrant contracts provide for net cash settlement for the particular contract or net share settlement, depending on the method of settlement, as discussed above, which is at the option of the Company. Based on existing guidance, the purchased call option contracts were recorded as a reduction of equity and the warrants were recorded as an addition to equity as of the trade date. Existing guidance states that a reporting entity shall not consider contracts to be derivative instruments if the contract issued or held by the reporting entity is both indexed to its own stock and classified in shareholders’ equity in its statement of financial position. The Company concluded the purchased call option contracts and the warrant contracts should be accounted for in shareholders’ equity.

The Company accounted for the Senior Convertible Notes in accordance with the authoritative guidance for convertible debt, which requires the proceeds from the issuance of the Senior Convertible Notes to be allocated between a liability component (issued at a discount) and an equity component. The resulting debt discount is amortized over the period the 2013 Senior Convertible Notes are expected to be outstanding as additional non-cash interest expense.

The following table provides equity and debt information for the 2013 Senior Convertible Notes under the convertible debt guidance.

 

 

 

 

 

 

 

 

 

 

2013 Senior Convertible Notes

 

(in millions)

 

October 28,
2011

 

April 29,
2011

 

Carrying amount of the equity component

 

$

547

 

$

547

 

 

 

 

 

 

 

 

 

Principal amount of the 2013 Senior Convertible Notes

 

$

2,200

 

$

2,200

 

Unamortized discount

 

 

(134

)

 

(177

)

Net carrying amount

 

$

2,066

 

$

2,023

 

As of October 28, 2011, the unamortized balance of the debt discount will be amortized over the remaining life of the 2013 Senior Convertible Notes, which is approximately two years. The following table provides interest rate and interest expense amounts related to the Senior Convertible Notes.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2011 Senior Convertible Notes

 

2013 Senior Convertible Notes

 

 

 

Three months ended

 

Three months ended

 

(in millions, except interest rate)

 

October 28,
2011

 

October 29,
2010

 

October 28,
2011

 

October 29,
2010

 

Effective interest rate

 

 

%

 

5.97

%

 

6.03

%

 

6.03

%

Interest cost related to contractual interest coupon

 

$

 

$

8

 

$

9

 

$

9

 

Interest cost related to amortization of the discount

 

$

 

$

23

 

$

21

 

$

20

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2011 Senior Convertible Notes

 

2013 Senior Convertible Notes

 

 

 

Six months ended

 

Six months ended

 

(in millions, except interest rate)

 

October 28,
2011

 

October 29,
2010

 

October 28,
2011

 

October 29,
2010

 

Effective interest rate

 

 

%

 

5.97

%

 

6.03

%

 

6.03

%

Interest cost related to contractual interest coupon

 

$

 

$

16

 

$

18

 

$

18

 

Interest cost related to amortization of the discount

 

$

 

$

46

 

$

43

 

$

40

 

16


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Senior Notes

The Company has outstanding unsecured senior obligations including the $550 million 4.500 percent 2009 Senior Notes due 2014, the $1.250 billion 3.000 percent 2010 Senior Notes due 2015, the $600 million 4.750 percent 2005 Senior Notes due 2015, the $500 million 2.625 percent 2011 Senior Notes due 2016, the $400 million 5.600 percent 2009 Senior Notes due 2019, the $1.250 billion 4.45 percent 2010 Senior Notes due 2020, the $500 million 4.125 percent 2011 Senior Notes due 2021, the $300 million 6.500 percent 2009 Senior Notes due 2039, and the $500 million 5.550 percent 2010 Senior Notes due 2040 (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which the Senior Notes were issued contain customary covenants, all of which the Company remains in compliance with as of October 28, 2011. The Company used the net proceeds from the sale of the Senior Notes for working capital and general corporate uses, which include the repayment of other indebtedness of the Company. For additional information regarding the terms of these agreements, refer to Note 8 of the Company’s Annual Report on Form 10-K for the year ended April 29, 2011.

As of October 28, 2011, the Company had interest rate swap agreements designated as fair value hedges of underlying fixed rate obligations including the Company’s $1.250 billion 3.000 percent 2010 Senior Notes due 2015, $600 million 4.750 percent 2005 Senior Notes due 2015, the Company’s $500 million 2.625 percent 2011 Senior Notes due 2016, and the Company’s $500 million 4.125 percent 2011 Senior Notes due 2021. For additional information regarding the interest rate swap agreements, refer to Note 9.

Contingent Convertible Debentures

As of April 29, 2011, the Company had $15 million remaining in aggregate principal amount of 1.250 percent Contingent Convertible Debentures, Series B due 2021 (the Debentures) outstanding. Each Debenture was convertible into shares of common stock at an initial conversion price of $61.81 per share. At the end of July 2011, the Company gave notice to the holders of the Debentures of its intent to redeem the Debentures for cash at a price equal to 100% of the principal amount, plus any accrued and unpaid interest, on September 15, 2011 (the Redemption Date). All of the outstanding Debentures were settled for cash on the Redemption Date and no holders converted Debentures into shares of the Company’s common stock.

Commercial Paper

The Company maintains a commercial paper program that allows the Company to have a maximum of $2.250 billion in commercial paper outstanding, with maturities up to 364 days from the date of issuance. As of October 28, 2011 and April 29, 2011, outstanding commercial paper totaled $1.750 billion and $1.500 billion, respectively. During the three and six months ended October 28, 2011, the weighted average original maturity of the commercial paper outstanding was approximately 107 days for both periods and the weighted average interest rate was 0.17 percent and 0.18 percent, respectively. The issuance of commercial paper reduces the amount of credit available under the Company’s existing lines of credit.

Bank Borrowings

Bank borrowings consist primarily of borrowings from non-U.S. banks at interest rates considered favorable by management and where natural hedges can be gained for foreign exchange purposes and borrowings from U.S. banks.

Lines of Credit

The Company has committed and uncommitted lines of credit with various banks. The committed lines of credit include a four-year $2.250 billion syndicated credit facility dated December 9, 2010 that will expire on December 9, 2014 (Credit Facility). The Credit Facility provides the Company with the ability to increase its capacity by an additional $500 million at any time during the life of the four-year term of the agreement. The Credit Facility provides backup funding for the commercial paper program, and therefore, the issuance of commercial paper reduces the amount of credit available under the committed lines of credit. As of October 28, 2011 and April 29, 2011, no amounts were outstanding on the committed lines of credit.

Interest rates on these borrowings are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard and Poor’s Ratings Group and Moody’s Investors Service. Facility fees are payable on the credit facilities and are determined in the same manner as the interest rates. The agreements also contain customary covenants, all of which the Company remains in compliance with as of October 28, 2011.

17


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 9 – Derivatives and Foreign Exchange Risk Management

The Company uses operational and economic hedges, as well as currency exchange rate derivative contracts and interest rate derivative instruments to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets, liabilities, and probable commitments. At inception of the forward contract, the derivative is designated as either a freestanding derivative or cash flow hedge. The primary currencies of the derivative instruments are the Euro and the Japanese Yen. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding as of October 28, 2011 and April 29, 2011 was $5.226 billion and $6.834 billion, respectively. The aggregate currency exchange rate (losses)/gains for the three and six months ended October 28, 2011 were $(77) million and $(133) million, respectively. The aggregate currency exchange rate gains/(losses) for the three and six months ended October 29, 2010 were $53 million and $107 million, respectively. These (losses)/gains represent the net impact to the condensed consolidated statements of earnings for the derivative instruments presented below, offset by remeasurement losses on foreign currency denominated assets and liabilities.

The information that follows explains the various types of derivatives and financial instruments used by the Company, how and why the Company uses such instruments, how such instruments are accounted for, and how such instruments impact the Company’s condensed consolidated balance sheets and statements of earnings.

Freestanding Derivative Forward Contracts

Freestanding derivative forward contracts are used to offset the Company’s exposure to the change in value of specific foreign currency denominated assets and liabilities. These derivatives are not designated as hedges, and therefore, changes in the value of these forward contracts are recognized currently in earnings, thereby offsetting the current earnings effect of the related change in U.S. dollar value of foreign currency denominated assets and liabilities. The cash flows from these contracts are reported as operating activities in the condensed consolidated statements of cash flows. The gross notional amount of these contracts, not designated as hedging instruments, outstanding as of October 28, 2011 and April 29, 2011 was $1.895 billion and $2.453 billion, respectively.

The amount of gains/(losses) and location of the gains/(losses) in the condensed consolidated statements of earnings related to derivative instruments not designated as hedging instruments for the three and six months ended October 28, 2011 and October 29, 2010 were as follows:

 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

 

 

 

Three months ended

 

Derivatives Not Designated as Hedging Instruments

 

Location

 

October 28, 2011

 

October 29, 2010

 

Foreign currency exchange rate contracts

 

 

Other expense

 

$

37

 

$

(42

)


 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

 

 

 

Six months ended

 

Derivatives Not Designated as Hedging Instruments

 

Location

 

October 28, 2011

 

October 29, 2010

 

Foreign currency exchange rate contracts

 

 

Other expense

 

$

20

 

$

(21

)

Cash Flow Hedges

Foreign Currency Exchange Rate Risk

Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. For derivative instruments that are designated and qualify as a cash flow hedge, the effective portion of the gain or loss on the derivative is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. No gains or losses relating to ineffectiveness of cash flow hedges were recognized in earnings during the three and six months ended October 28, 2011 or October 29, 2010. No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness and no hedges were derecognized or discontinued during the three and six months ended October 28, 2011 or October 29, 2010. The cash flows from these contracts are reported as operating activities in the condensed consolidated statements of cash flows. The gross notional amount of these contracts, designated as cash flow hedges, outstanding as of October 28, 2011 and April 29, 2011 was $3.331 billion and $4.381 billion, respectively, and will mature within the subsequent 29-month period.

The amount of gains/(losses) and location of the gains/(losses) in the condensed consolidated statements of earnings and other comprehensive income (OCI) related to derivative instruments designated as cash flow hedges for the three and six months ended October 28, 2011 and October 29, 2010 are as follows:

18


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

Three months ended
October 28, 2011

 

 

 

 

 

 

 

 

 

 

 

 

Gross Gains/(Losses) Recognized in OCI
on Effective Portion of Derivative

 

 

Effective Portion of Gains/(Losses) on Derivative Reclassified from
Accumulated Other Comprehensive Loss into Income

 

(in millions)
Derivatives in Cash Flow
Hedging Relationships

 

Amount

 

 

Location

 

Amount

 

Foreign currency exchange rate contracts

 

$

111

 

 

Other expense

 

$

(55

)

 

 

 

 

 

 

Cost of products sold

 

 

7

 

Total

 

$

111

 

 

 

$

(48

)


 

 

 

 

 

 

 

 

 

 

 

Three months ended
October 29, 2010

 

 

 

 

 

 

 

 

 

 

 

 

Gross Gains/(Losses) Recognized in OCI
on Effective Portion of Derivative

 

 

Effective Portion of Gains/(Losses) on Derivative Reclassified from
Accumulated Other Comprehensive Loss into Income

 

(in millions)
Derivatives in Cash Flow
Hedging Relationships

 

Amount

 

 

Location

 

Amount

 

Foreign currency exchange rate contracts

 

$

(261

)

 

Other income

 

$

16

 

 

 

 

 

 

 

Cost of products sold

 

 

6

 

Total

 

$

(261

)

 

 

 

$

22

 


 

 

 

 

 

 

 

 

 

 

 

Six months ended
October 28, 2011

 

 

 

 

 

 

 

 

 

 

 

 

Gross Gains/(Losses) Recognized in OCI
on Effective Portion of Derivative

 

 

Effective Portion of Gains/(Losses) on Derivative Reclassified from
Accumulated Other Comprehensive Loss into Income

 

(in millions)
Derivatives in Cash Flow
Hedging Relationships

 

Amount

 

 

Location

 

Amount

 

Foreign currency exchange rate contracts

 

$

131

 

 

Other expense

 

$

(109

)

 

 

 

 

 

 

Cost of products sold

 

 

15

 

Total

 

$

131

 

 

 

 

$

(94

)


 

 

 

 

 

 

 

 

 

 

 

Six months ended
October 29, 2010

 

 

 

 

 

 

 

 

 

 

 

 

Gross Gains/(Losses) Recognized in OCI
on Effective Portion of Derivative

 

 

Effective Portion of Gains/(Losses) on Derivative Reclassified from
Accumulated Other Comprehensive Loss into Income

 

(in millions)
Derivatives in Cash Flow
Hedging Relationships

 

Amount

 

 

Location

 

Amount

 

Foreign currency exchange rate contracts

 

$

(336

)

 

Other income

 

$

70

 

 

 

 

 

 

 

Cost of products sold

 

 

5

 

Total

 

$

(336

)

 

 

 

$

75

 

Forecasted Debt Issuance Interest Rate Risk
Forward starting interest rate derivative instruments designated as cash flow hedges are designed to manage the exposure to interest rate volatility with regard to future issuances of fixed-rate debt. For forward starting interest rate derivative instruments that are designated and qualify as a cash flow hedge, the effective portion of the gain or loss on the derivative is reported as a component of accumulated other comprehensive loss and beginning in the period or periods in which the planned debt issuance occurs, the gain or loss is then reclassified into interest expense, net over the term of the related debt. In the second quarter of fiscal year 2012, the Company entered into $750 million of pay fixed, forward starting interest rate swaps with a weighted average fixed rate of 2.84 percent in advance of a planned debt issuance.

19


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

The market value of outstanding forward starting interest rate swap derivative instruments at October 28, 2011 was a $10 million unrealized loss. This unrealized loss was recorded in other long-term liabilities with the offset recorded in other comprehensive income (OCI) in the condensed consolidated balance sheet.

As of October 28, 2011 and April 29, 2011, the Company had a balance of $177 million and $257 million in after-tax net unrealized losses associated with cash flow hedging instruments recorded in OCI. The Company expects that $141 million of this balance will be reclassified into the consolidated statement of earnings over the next 12 months.

Fair Value Hedges

For derivative instruments that are designated and qualify as fair value hedges, the gain or loss on the derivatives as well as the offsetting gain or loss on the hedged item attributable to the hedged risk are recognized in current earnings.

Interest rate derivative instruments designated as fair value hedges are designed to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount.

As of October 28, 2011 and April 29, 2011, the Company had interest rate swaps in gross notional amounts of $1.950 billion and $3.500 billion, respectively, designated as fair value hedges of underlying fixed rate obligations. As of October 28, 2011, outstanding interest rate swap agreements were designated as fair value hedges of underlying fixed rate obligations including the Company’s $1.250 billion 3.000 percent 2010 Senior Notes due 2015, $600 million 4.750 percent 2005 Senior Notes due 2015, $500 million 2.625 percent 2011 Senior Notes due 2016, and the $500 million 4.125 percent 2011 Senior Notes due 2021. For additional information regarding the terms of the Company’s interest rate swap agreements, refer to Note 9 of the Company’s Annual Report on Form 10-K for the year ended April 29, 2011.

In July 2011, the Company terminated interest rate swap agreements with a consolidated notional amount of $900 million that were designated as fair value hedges of the fixed interest rate obligation under the Company’s $2.200 billion 1.625 percent 2013 Senior Convertible Notes and $550 million 4.500 percent Senior Notes due 2014. Upon termination, the contracts were in an asset position, resulting in cash receipts of $46 million, which included $10 million of accrued interest. The gain from terminating the interest rate swap agreements increased the outstanding balance of the 2013 Senior Convertible Notes and the Senior Notes and is being amortized as a reduction of interest expense over the remaining life of the 2013 Senior Convertible Notes and the Senior Notes. The cash flows from the termination of these interest rate swap agreements have been reported as operating activities in the condensed consolidated statements of cash flows.

In August 2011, the Company terminated interest rate swap agreements with a consolidated notional amount of $650 million that were designated as fair value hedges of the fixed interest rate obligation under the Company’s $1.250 billion 3.000 percent 2010 Senior Notes due 2015. Upon termination, the contracts were in an asset position, resulting in cash receipts of $42 million, which included $7 million of accrued interest. The gain from terminating the interest rate swap agreement increased the outstanding balance of the 2015 Senior Notes and is being amortized as a reduction of interest expense over the remaining life of the notes. The cash flows from the termination of this interest rate swap agreement has been reported as operating activities in the condensed consolidated statements of cash flows.

The market value of outstanding interest rate swap agreements was a $136 million unrealized gain and the market value of the hedged item was a $136 million unrealized loss at October 28, 2011, which were recorded in other assets with the offset recorded in long-term debt in the condensed consolidated balance sheet. No hedge ineffectiveness was recorded as a result of these fair value hedges for the three months ended October 28, 2011 and less than $1 million was recorded for the six months ended October 28, 2011. Hedge ineffectiveness was not material for the three months ended October 29, 2010 and $2 million of hedge ineffectiveness was recorded for the six months ended October 29, 2010, which were recorded as an increase in interest expense, net in the condensed consolidated statement of earnings.

During the three and six months ended October 28, 2011 and October 29, 2010, the Company did not have any ineffective fair value hedging instruments. In addition, the Company did not recognize any gains or losses during the three and six months ended October 28, 2011 and October 29, 2010 on firm commitments that no longer qualify as fair value hedges.

20


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Balance Sheet Presentation

The following table summarizes the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets as of October 28, 2011 and April 29, 2011. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not, and are further segregated by type of contract within those two categories.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

October 28, 2011

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asset Derivatives

 

Liability Derivatives

 

(in millions)

 

 

Balance Sheet Location

 

Fair Value

 

Balance Sheet Location

 

Fair Value

 

 

 

 

 

 

 

 

 

 

 

 

Derivatives designated as hedging instruments

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency exchange rate contracts

 

 

Prepaid expenses and other current assets

 

$

34

 

 

Other accrued expenses

 

$

140

 

Interest rate contracts

 

 

Other assets

 

 

136

 

 

Other long-term liabilities

 

 

10

 

Foreign currency exchange rate contracts

 

 

Other assets

 

 

7

 

 

Other long-term liabilities

 

 

38

 

Total derivatives designated as hedging instruments

 

 

 

 

$

177

 

 

 

 

$

188

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivatives not designated as hedging instruments

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency exchange rate contracts

 

 

Prepaid expenses and other current assets

 

$

 

 

Other accrued expenses

 

$

2

 

Total derivatives not designated as hedging instruments

 

 

 

 

$

 

 

 

 

$

2

 

Total derivatives

 

 

 

 

$

177

 

 

 

 

$

190

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

April 29, 2011

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asset Derivatives

 

Liability Derivatives

 

(in millions)

 

 

Balance Sheet Location

 

Fair Value

 

Balance Sheet Location

 

Fair Value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivatives designated as hedging instruments

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency exchange rate contracts

 

 

Prepaid expenses and other current assets

 

$

19

 

 

Other accrued expenses

 

$

235

 

Interest rate contracts

 

 

Other assets

 

 

109

 

 

 

 

 

 

 

Foreign currency exchange rate contracts

 

 

Other assets

 

 

1

 

 

Other long-term liabilities

 

 

64

 

Total derivatives designated as hedging instruments

 

 

 

 

$

129

 

 

 

 

$

299

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivatives not designated as hedging instruments

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency exchange rate contracts

 

 

Prepaid expenses and other current assets

 

$

1

 

 

Other accrued expenses

 

$

4

 

Total derivatives not designated as hedging instruments

 

 

 

 

$

1

 

 

 

 

$

4

 

Total derivatives

 

 

 

 

$

130

 

 

 

 

$

303

 

21


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Concentrations of Credit Risk

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist principally of interest-bearing investments, forward exchange derivative contracts, and trade accounts receivable.

The Company maintains cash and cash equivalents, investments, and certain other financial instruments (including currency exchange rate and interest rate derivative contracts) with various major financial institutions. The Company performs periodic evaluations of the relative credit standings of these financial institutions and limits the amount of credit exposure with any one institution. In addition, the Company has collateral credit agreements with its primary derivatives counterparties. Under these agreements, either party is required to post eligible collateral when the market value of transactions covered by the agreement exceeds specific thresholds, thus limiting credit exposure for both parties. As of October 28, 2011, no collateral was posted by either the Company or its counterparties. As of April 29, 2011, the Company had $8 million in securities pledged as collateral to its counterparties, respectively. The securities pledged as collateral are included in cash and cash equivalents in the condensed consolidated balance sheets.

Concentrations of credit risk with respect to trade accounts receivable are limited due to the large number of customers and their dispersion across many geographic areas. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. However, a significant amount of trade receivables are with hospitals that are dependent upon governmental health care systems in many countries. The current economic conditions in many foreign countries, particularly the recent deterioration of conditions in Portugal, Italy, Greece, and Spain, have increased, and may continue to increase, the average length of time it takes the Company to collect on its outstanding accounts receivable in these countries. As of October 28, 2011, the Company’s accounts receivable net of the allowance for doubtful accounts in Portugal, Italy, Greece, and Spain was $1.004 billion. The Company continues to monitor the creditworthiness of customers located in these and other geographic areas. Although the Company does not currently foresee a significant credit risk associated with these receivables, repayment is dependent upon the financial stability of the economies of these countries. As of October 28, 2011 and April 29, 2011, no one customer nor any one national health care system represented more than 10 percent of the Company’s outstanding accounts receivable. See “Operations Outside of the United States” in management’s discussion and analysis for further details regarding the concentrations of credit risk in the Company’s trade accounts receivable.

Note 10 – Inventories

Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows:

 

 

 

 

 

 

 

 

(in millions)

 

October 28,
2011

 

April 29,
2011

 

Finished goods

 

$

1,149

 

$

1,067

 

Work in process

 

 

299

 

 

263

 

Raw materials

 

 

392

 

 

365

 

Total

 

$

1,840

 

$

1,695

 

Note 11 – Goodwill and Other Intangible Assets

The changes in the carrying amount of goodwill for the six months ended October 28, 2011 are as follows:

 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

Cardiac and
Vascular Group

 

Restorative
Therapies Group

 

Total

 

Balance as of April 29, 2011

 

$

2,679

 

$

6,858

 

$

9,537

 

Goodwill as a result of acquisitions

 

 

 

 

398

 

 

398

 

Purchase accounting adjustments, net

 

 

6

 

 

23

 

 

29

 

Currency adjustment, net

 

 

(25

)

 

5

 

 

(20

)

Balance as of October 28, 2011

 

$

2,660

 

$

7,284

 

$

9,944

 

22


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

During the three months ended October 28, 2011, the Company recorded $29 million in purchase accounting adjustments, net. This primarily relates to a valuation correction for the calculation of deferred tax assets associated with net operating losses available to the Company for the fiscal year 2008 acquisition of Kyphon, Inc. (Kyphon).

Balances of intangible assets, excluding goodwill, as of October 28, 2011 and April 29, 2011 are as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

Purchased
Technology and
Patents

 

Trademarks
and
Tradenames

 

Acquired
IPR&D

 

Other

 

Total

 

Amortizable intangible assets as of October 28, 2011:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Original cost

 

$

3,691

 

$

374

 

$

378

 

$

154

 

$

4,597

 

Accumulated amortization

 

 

(1,316

)

 

(304

)

 

 

 

(102

)

 

(1,722

)

Carrying value

 

$

2,375

 

$

70

 

$

378

 

$

52

 

$

2,875

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortizable intangible assets as of April 29, 2011:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Original cost

 

$

3,565

 

$

373

 

$

338

 

$

150

 

$

4,426

 

Accumulated amortization

 

 

(1,265

)

 

(290

)

 

 

 

(94

)

 

(1,649

)

Carrying value

 

$

2,300

 

$

83

 

$

338

 

$

56

 

$

2,777

 

Amortization expense for the three and six months ended October 28, 2011 was $86 million and $174 million, respectively, and for the three and six months ended October 29, 2010 was $85 million and $167 million, respectively.

Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets, excluding any possible future amortization associated with acquired IPR&D, which has not met technological feasibility, is as follows:

 

 

 

 

 

(in millions)
Fiscal Year

 

Estimated
Amortization Expense

 

Remaining 2012

 

$

152

 

2013

 

 

319

 

2014

 

 

308

 

2015

 

 

292

 

2016

 

 

280

 

Thereafter

 

 

1,146

 

Total estimated amortization expense

 

$

2,497

 

Note 12 – Warranty Obligation

The Company offers a warranty on various products. The Company estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product is sold. Factors that affect the Company’s warranty liability include the number of units sold, historical and anticipated rates of warranty claims, and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. The amount of the reserve recorded is equal to the net costs to repair or otherwise satisfy the claim. The Company includes the covered costs associated with field actions, if any, in cost of products sold on the condensed consolidated statements of earnings. The Company includes the warranty obligation in other accrued expenses and other long-term liabilities on the condensed consolidated balance sheets.

Changes in the Company’s product warranties during the six months ended October 28, 2011 and October 29, 2010 consisted of the following:

 

 

 

 

 

 

 

 

 

 

Six months ended

 

(in millions)

 

October 28,
2011

 

October 29,
2010

 

Balance at the beginning of the period

 

$

44

 

$

45

 

Warranty claims provision

 

 

11

 

 

15

 

Settlements made

 

 

(16

)

 

(14

)

Balance at the end of the period

 

$

39

 

$

46

 

23


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 13 – Interest Expense, Net

Interest income and interest expense for the three and six months ended October 28, 2011 and October 29, 2010 are as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

Six months ended

 

(in millions)

 

October 28, 2011

 

October 29, 2010

 

October 28, 2011

 

October 29, 2010

 

Interest income

 

$

(47

)

$

(46

)

$

(92

)

$

(79

)

Interest expense

 

 

85

 

 

113

 

 

162

 

 

220

 

Interest expense, net

 

$

38

 

$

67

 

$

70

 

$

141

 

Interest income includes interest earned on the Company’s cash and cash equivalents, short-and long-term investments, the net realized and unrealized gain or loss on trading securities, changes in the fair value of interest rate derivative instruments, and the net realized gain or loss on the sale or impairment of available-for-sale debt securities. See Note 6 for further discussion of these items.

Interest expense includes the expense associated with the interest that the Company pays on its outstanding borrowings, including short-and long-term instruments, change in the fair value of interest rate derivative instruments, and the amortization of debt issuance costs and debt discounts.

Note 14 – Income Taxes

During the three months ended October 28, 2011, the Company recorded a $17 million net benefit associated with the resolution of certain income tax audits, changes to uncertain tax position reserves, and the finalization of certain tax returns. These tax adjustments are operational in nature and are recorded in provision for income taxes on the condensed consolidated statement of earnings.

During the six months ended October 28, 2011, the Company’s gross unrecognized tax benefits increased from $769 million to $786 million. In addition, the Company has accrued interest and penalties of $103 million as of October 28, 2011. If all of the Company’s unrecognized tax benefits were recognized, approximately $709 million would impact the Company’s effective tax rate. The Company records the gross unrecognized tax benefit as a long-term liability as it does not expect significant payments to occur or the total amount of unrecognized tax benefits to change significantly over the next 12 months.

The Company will continue to recognize interest and penalties related to income tax matters in the provision for income taxes in the condensed consolidated statements of earnings and record the liability in the current or long-term accrued income taxes in the condensed consolidated balance sheets, as appropriate.

Tax audits associated with the allocation of income, and other complex issues, may require an extended period of time to resolve and may result in income tax adjustments if changes to the Company’s allocation are required between jurisdictions with different tax rates. Tax authorities periodically review the Company’s tax returns and propose adjustments to its tax filings. The Internal Revenue Service (IRS) has settled its audits with the Company for all years through fiscal year 2004. Tax years settled with the IRS may remain open for foreign tax audits and competent authority proceedings. Competent authority proceedings are a means to resolve intercompany pricing disagreements between countries.

In September 2005, the IRS issued its audit report for fiscal years 2000, 2001, and 2002. In addition, the IRS issued its audit report for fiscal years 2003 and 2004 in March 2007. During October 2011, the Company reached agreement with the IRS on all remaining final proposed adjustments for fiscal years 2000 through 2004.

In March 2009, the IRS issued its audit report for fiscal years 2005 and 2006. The Company reached agreement with the IRS on some but not all matters. The unresolved significant issues that remain outstanding relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company’s key manufacturing sites, as well as the timing of the deductibility of a settlement payment. On December 23, 2010, the IRS issued a statutory notice of deficiency with respect to the remaining issues. The Company filed a Petition with the U.S. Tax Court on March 21, 2011 objecting to the deficiency.

24


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

In October 2011, the IRS issued its audit report for fiscal years 2007 and 2008. The Company reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary in Puerto Rico, and proposed adjustments associated with the tax effects of the Company's acquisition of Kyphon. Associated with the Kyphon acquisition, Medtronic entered into an intercompany transaction whereby the Kyphon U.S. tangible assets were sold to another wholly-owned subsidiary in a taxable transaction. The IRS has disagreed with the Company's valuation and proposed that all U.S. goodwill, the value of the ongoing business, and the value of the workforce in place be included in the tangible asset sale. The Company disagrees that such items were sold, as well as with the IRS valuation of these items.

The Company’s reserve for the uncertain tax positions related to these significant unresolved matters with the IRS, described above, is subject to a high degree of estimation and management judgment. Resolution of these significant unresolved matters, or positions taken by the IRS or foreign tax authorities during future tax audits, could have a material impact on the Company’s financial results in future periods. The Company continues to believe that its reserves for uncertain tax positions are appropriate and have meritorious defenses for its tax filings and will vigorously defend them during the audit process, appellate process, and through litigation in courts, as necessary.

Note 15 – Earnings Per Share

Basic earnings per share is computed based on the weighted average number of common shares outstanding. Diluted earnings per share is computed based on the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include stock options and other stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.

The table below sets forth the computation of basic and diluted earnings per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

Six months ended

 

(in millions, except per share data)

 

October 28,
2011

 

October 29,
2010

 

October 28,
2011

 

October 29,
2010

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings

 

$

871

 

$

566

 

$

1,692

 

$

1,396

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic – weighted average shares outstanding

 

 

1,058.1

 

 

1,080.1

 

 

1,060.6

 

 

1,083.1

 

Effect of dilutive securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee stock options

 

 

0.2

 

 

0.3

 

 

0.7

 

 

0.5

 

Employee restricted stock awards/units

 

 

4.6

 

 

3.1

 

 

4.7

 

 

2.9

 

Other

 

 

0.2

 

 

0.2

 

 

0.2

 

 

0.2

 

Diluted – weighted average shares outstanding

 

 

1,063.1

 

 

1,083.7

 

 

1,066.2

 

 

1,086.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings per share

 

$

0.82

 

$

0.52

 

$

1.60

 

$

1.29

 

Diluted earnings per share

 

$

0.82

 

$

0.52

 

$

1.59

 

$

1.28

 

The calculation of weighted average diluted shares outstanding excludes options for approximately 63 million and 53 million shares of common stock for the three and six months ended October 28, 2011, respectively, and approximately 69 million and 62 million for the three and six months ended October 29, 2010, respectively, because their effect would be anti-dilutive on the Company’s earnings per share. For the three and six months ended October 28, 2011 and October 29, 2010, common share equivalents related to the Company’s $2.200 billion and $4.400 billion of Senior Convertible Notes, respectively, were anti-dilutive as the market price of the Company’s stock was below the conversion price of the Senior Convertible Notes and, therefore, were excluded from the calculation of weighted average diluted shares.

Note 16 – Comprehensive Income and Accumulated Other Comprehensive Loss

In addition to net earnings, comprehensive income includes changes in currency exchange rate translation adjustments, unrealized gains and losses on currency exchange rate derivative contracts and interest rate derivative instruments qualifying and designated as cash flow hedges, net changes in retirement obligation funded status, and unrealized gains and losses on available-for-sale marketable securities. Comprehensive income for the three months ended October 28, 2011 and October 29, 2010 was $799 million and $522 million, respectively. Comprehensive income for the six months ended October 28, 2011 and October 29, 2010 was $1.759 billion and $1.306 billion, respectively.

25


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Presented below is a summary of activity for each component of accumulated other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in millions)

 

Unrealized
Gain/(Loss) on
Investments

 

Cumulative
Translation
Adjustments

 

Net Change in
Retirement
Obligations

 

Unrealized
Gain/(Loss) on
Derivatives

 

Accumulated Other
Comprehensive Loss

 

Balance as of April 29, 2011

 

$

196

 

$

443

 

$

(607

)

$

(257

)

$

(224

)

Other comprehensive income

 

 

105

 

 

14

 

 

8

 

 

13

 

 

139

 

Balance as of July 29, 2011

 

$

301

 

$

457

 

$

(599

)

$

(244

)

$

(85

)

Other comprehensive (loss)/income

 

 

(57

)

 

(97

)

 

15

 

 

67

 

 

(72

)

Balance as of October 28, 2011

 

$

244

 

$

360

 

$

(584

)

$

(177

)

$

(157

)

Translation adjustments are not adjusted for income taxes as substantially all translation adjustments relate to permanent investments in non-U.S. subsidiaries. The tax expense on the net unrealized gain on foreign exchange rate derivatives and interest rate derivative instruments for the three and six months ended October 28, 2011 was $42 million and $48 million, respectively. The tax expense related to the net change in retirement obligations was $6 million and $12 million for the three and six months ended October 28, 2011. The tax impact on the unrealized gain/(loss) on investments for the three and six months ended October 28, 2011 was $28 million of benefit and $28 million of expense, respectively. During the first quarter of fiscal year 2012, the Company received shares in the form of a dividend related to a previous cost method investment, and in accordance with authoritative guidance, the Company recorded these shares as an investment and correspondingly recorded an unrealized gain.

Note 17 – Stock-Based Compensation

Under the fair value recognition provisions of U.S. GAAP for accounting for stock-based compensation, the Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period.

The following table presents the components and classification of stock-based compensation expense recognized for the three and six months ended October 28, 2011 and October 29, 2010:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

Six months ended

 

(in millions)

 

October 28,
2011

 

October 29,
2010

 

October 28,
2011

 

October 29,
2010

 

Stock options

 

$

21

 

$

28

 

$

36

 

$

50

 

Restricted stock awards/units

 

 

25

 

 

24

 

 

47

 

 

47

 

Employee stock purchase plan

 

 

3

 

 

3

 

 

7

 

 

7

 

Total stock-based compensation expense

 

$

49

 

$

55

 

$

90

 

$

104

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of products sold

 

$

4

 

$

6

 

$

7

 

$

12

 

Research and development expense

 

 

9

 

 

14

 

 

16

 

 

26

 

Selling, general, and administrative expense

 

 

36

 

 

35

 

 

67

 

 

66

 

Total stock-based compensation expense

 

$

49

 

$

55

 

$

90

 

$

104

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax benefits

 

 

(15

)

 

(16

)

 

(26

)

 

(30

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total stock-based compensation expense, net of tax

 

$

34

 

$

39

 

$

64

 

$

74

 

26


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 18 – Retirement Benefit Plans

The Company sponsors various retirement benefit plans, including defined benefit pension plans (pension benefits), post-retirement medical plans (post-retirement benefits), defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the plans include the following components for the three and six months ended October 28, 2011 and October 29, 2010:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Pension Benefits

 

Non-U.S. Pension Benefits

 

Post-Retirement Benefits

 

 

 

Three months ended

 

Three months ended

 

Three months ended

 

(in millions)

 

October 28,
2011

 

October 29,
2010

 

October 28,
2011

 

October 29,
2010

 

October 28,
2011

 

October 29,
2010

 

Service cost

 

$

23

 

$

22

 

$

11

 

$

9

 

$

5

 

$

5

 

Interest cost

 

 

22

 

 

19

 

 

7

 

 

6

 

 

4

 

 

4

 

Expected return on plan assets

 

 

(30

)

 

(26

)

 

(9

)

 

(6

)

 

(4

)

 

(3

)

Amortization of net actuarial loss

 

 

11

 

 

8

 

 

1

 

 

1

 

 

1

 

 

1

 

Net periodic benefit cost

 

$

26

 

$

23

 

$

10

 

$

10

 

$

6

 

$

7

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Pension Benefits

 

Non-U.S. Pension Benefits

 

Post-Retirement Benefits

 

 

 

Six months ended

 

Six months ended

 

Six months ended

 

(in millions)

 

October 28,
2011

 

October 29,
2010

 

October 28,
2011

 

October 29,
2010

 

October 28,
2011

 

October 29,
2010

 

Service cost

 

$

46

 

$

44

 

$

22

 

$

18

 

$

10

 

$

10

 

Interest cost

 

 

44

 

 

38

 

 

14

 

 

12

 

 

8

 

 

8

 

Expected return on plan assets

 

 

(60

)

 

(52

)

 

(18

)

 

(12

)

 

(8

)

 

(6

)

Amortization of net actuarial loss

 

 

22

 

 

16

 

 

2

 

 

2

 

 

2

 

 

2

 

Net periodic benefit cost

 

$

52

 

$

46

 

$

20

 

$

20

 

$

12

 

$

14

 

Note 19 – Contingencies

The Company is involved in a number of legal actions. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief (including injunctions barring the sale of products that are the subject of the lawsuit), that could require significant expenditures or result in lost revenues. In accordance with U.S. GAAP, the Company records a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery; involve unsubstantiated or indeterminate claims for damages; potentially involve penalties, fines or punitive damages; or could result in a change in business practice. While it is not possible to predict the outcome for most of the matters discussed, the Company believes it is possible that costs associated with them could have a material adverse impact on the Company’s consolidated earnings, financial position, or cash flows.

Litigation with Wyeth and Cordis Corporation

On February 22, 2008, Wyeth and Cordis Corporation (Cordis) filed a lawsuit against the Company and its subsidiary, Medtronic AVE, Inc., in U.S. District Court for the District of New Jersey, alleging that Medtronic’s Endeavor drug-eluting stent infringes three U.S. “Morris” patents alleged to be owned by Wyeth and exclusively licensed to Cordis. The District Court has advised it will issue an order granting certain motions for summary judgment in favor of the defendants, including Medtronic. The Company is indemnified for the claims made by Wyeth and Cordis. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter.

27


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Litigation with Edwards Lifesciences, Inc.

On March 19, 2010, the U.S. District Court for the District of Delaware added Medtronic CoreValve LLC (CoreValve) as a party to litigation pending between Edwards Lifesciences, Inc. (Edwards) and CoreValve, Inc. In the litigation, Edwards asserted that CoreValve’s transcatheter aortic valve replacement product infringed three U.S. “Andersen” patents owned by Edwards. Before trial, the court granted summary judgment to Medtronic as to two of the three patents. Following a trial, on April 1, 2010 a jury found that CoreValve willfully infringed a claim on the remaining Andersen patent and awarded total lost profit and royalty damages of $74 million. On May 28, 2010, Edwards filed a motion seeking an injunction against CoreValve. On February 7, 2011, the trial court ruled on post-trial motions, denying Edwards’ motions for an injunction, enhanced damages and attorneys’ fees and denying Medtronic’s motions to overturn the jury’s verdict. Medtronic has appealed to the U.S. Court of Appeals for the Federal Circuit. The Federal Circuit will hear oral argument on this appeal on January 11, 2012.

On March 12, 2010, Edwards served a second lawsuit in the Delaware court upon CoreValve, Medtronic Vascular, and Medtronic, asserting that Medtronic’s transcatheter aortic valve replacement product from CoreValve infringed three U.S. Andersen patents owned by Edwards, including two of the patents that were the subject of the first lawsuit. Medtronic filed a motion to dismiss or stay the second lawsuit on May 24, 2010.

Edwards also previously asserted that the CoreValve product infringed an Andersen patent in Germany and the United Kingdom, which is a counterpart to the U.S. Andersen patents. Courts in both countries found that the CoreValve product does not infringe the European Andersen patent. On February 11, 2010, a German appellate court issued its opinion affirming the trial court ruling that the CoreValve product does not infringe the Andersen patent in Germany. On June 30, 2010, the United Kingdom appellate court affirmed a trial court ruling that the CoreValve product does not infringe the Andersen patent in the United Kingdom. Both cases have been dismissed.

The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter.

Sprint Fidelis Product Liability Matters

On October 15, 2007, the Company voluntarily suspended worldwide distribution of its Sprint Fidelis (Fidelis) family of defibrillation leads. Approximately 4,000 lawsuits regarding the Fidelis leads were filed against the Company, including approximately 47 putative class action suits reflecting a total of approximately 9,000 individual personal injury cases. Approximately 2,800 of the lawsuits were commenced in Minnesota state court and approximately 1,200 were consolidated for pretrial proceedings before a single federal judge in the U.S. District Court for the District of Minnesota pursuant to the Multi-District Litigation (MDL) rules. On January 5, 2009, the MDL court dismissed with prejudice the master consolidated complaint for individuals and the master consolidated complaint for third-party payors on grounds of federal preemption. The state court judge dismissed the state court cases on similar grounds on October 22, 2009. The federal opinion was affirmed on appeal and the state appeal was dismissed.

The Company announced on October 14, 2010 that it had entered into an agreement to settle the pending lawsuits as well as certain unfiled claims subject to opt-out rights by both plaintiffs and the Company, including the Company’s right to cancel the agreement. The parties subsequently reached an adjusted settlement agreement pursuant to which Medtronic waived its right to cancel the agreement and agreed to pay a total of $221 million to resolve over 14,000 filed and unfiled claims. Accordingly, the Company recorded an expense of $221 million related to probable and reasonably estimated damages under U.S. GAAP in connection with these matters in fiscal year 2011. Subsequent to October 28, 2011, the Company fully paid the plaintiffs.

In addition, one putative class action has been filed in the Ontario Superior Court of Justice in Canada. On October 20, 2009, that court certified a class proceeding, but denied class certification on plaintiffs’ claim for punitive damages. Pretrial proceedings are underway. The Company has not recorded an expense related to damages in connection with that matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter.

Shareholder Related Matters

On December 10, 2008, the Minneapolis Firefighters’ Relief Association filed a putative class action complaint against the Company and certain current and former officers in the U.S. District Court for the District of Minnesota, alleging violations of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. The complaint alleges that the defendants made false and misleading public statements concerning the INFUSE Bone Graft product which artificially inflated Medtronic’s stock price during the period. On August 21, 2009, plaintiffs filed a consolidated putative class action complaint expanding the class. Medtronic’s motion to dismiss the consolidated complaint was denied on February 3, 2010, and pretrial proceedings are underway.

28


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

The Company has not recorded an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter.

Mirowski

Medtronic is a licensee to the RE 38,119 patent (‘119 Patent) and RE 38,897 patent (‘897 Patent) owned by Mirowski Family Ventures, LLC (Mirowski) relating to the treatment of hemodynamic dysfunction. Medtronic and Mirowski dispute the application of the ‘119 and ‘897 Patents to certain Medtronic cardiac resynchronization products. On December 17, 2007, Medtronic filed an action in U.S. District Court for the District of Delaware seeking a declaration that none of its products infringe any valid claims of either the ‘119 or ‘897 Patents. If certain conditions are fulfilled, the ‘119 and/or ‘897 Patents are determined to be valid and the Medtronic products are found to infringe the ‘119 and/or ‘897 Patents, Medtronic will be obligated to pay royalties to Mirowski based upon sales of certain cardiac resynchronization therapy-defibrillator (CRT-D) products. A bench trial concluded on March 13, 2010. On March 30, 2011, the trial court entered a judgment of non-infringement in Medtronic’s favor. Mirowski has appealed the decision to the United States Court of Appeals for the Federal Circuit. As of October 28, 2011 the amount of disputed royalties and interest related to CRT-D products was $117 million. This amount has not been accrued pursuant to U.S. GAAP requirements because the outcome is not currently probable.

Other Matters

On October 24, 2005, the Company received a subpoena from the United States Attorney’s Office for the District of Massachusetts issued under the Health Insurance Portability & Accountability Act of 1996 (HIPAA) relating to post-market clinical studies of pacemakers, defibrillators, and related equipment and services. In September 2008, the United States Attorney’s office for the District of Massachusetts informed Medtronic that it was no longer pursuing this investigation, but on September 5, 2008, the Office of Inspector General for the Department of Health and Human Services in the District of Minnesota sent Medtronic a subpoena requesting substantially the same materials covered in the 2005 Massachusetts subpoena, and the U.S. Attorney’s Office for the District of Minnesota took over the investigation. In accordance with U.S. GAAP, in fiscal year 2011 the Company recorded $24 million in expense, paid subsequent to October 28, 2011 pursuant to a settlement agreement with the Department of Justice.

On September 25, 2007 and November 16, 2007, the Company received letters from the U.S. Securities and Exchange Commission (SEC) and U.S. Department of Justice, respectively, requesting information relating to any potential violations of the U.S. Foreign Corrupt Practices Act in connection with the sale of medical devices in several non-U.S. countries. A number of competitors have publicly disclosed receiving similar letters. Subsequently, the SEC and Department of Justice have made additional requests for information from the Company. The Company is fully cooperating with the requests.

In late June 2008, the Company received a subpoena issued by the United States Attorney’s Office for the District of Massachusetts pursuant to HIPAA, relating to the Company’s marketing of biliary stents. The Company is fully cooperating with this inquiry. On February 19, 2010, a complaint asserting similar issues, captioned United States of America ex rel Nowak & Dodd v. Medtronic, was unsealed in the United States District Court for the District of Massachusetts. On July 27, 2011, the Court issued an order granting Medtronic’s motion to dismiss one relator’s claims in their entirety and dismissing most of the other relator’s claims. On November 4, 2011, the Company entered into a non-financial settlement with one of the relators, under which he abandoned all of his claims against the Company.

On October 6, 2008, the Company received a subpoena from the United States Attorney’s Office for the District of Massachusetts pursuant to HIPAA requesting production of documents relating to Medtronic’s INFUSE Bone Graft product. The Company has since received supplemental subpoenas or document requests in connection with the INFUSE Bone Graft product, including a December 18, 2008 civil investigative demand from the Massachusetts Attorney General’s Office, an October 14, 2011 subpoena issued by the California Attorney General’s office, and several inquiries from the United States Senate Finance Committee. The Company is fully cooperating with these investigations.

On June 16, 2009, the Company received an administrative subpoena from the New Jersey Attorney General, Division of Consumer Affairs, requesting production of documents relating to the Company’s clinical studies, its financial arrangements with certain physicians and health care providers, and clinical research done by certain physicians and health care providers. The Company is fully cooperating with this inquiry.

29


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

On September 16, 2009, the Company received a subpoena from the Office of Inspector General for the Department of Health and Human Services in the Eastern District of California requesting production of documents relating to the Company’s cardiac rhythm medical devices, including revenue, sales, marketing, and promotional documents, documents relating to reimbursement communications to customers pertaining to the devices, documents relating to scientific studies and registries pertaining to the devices, and documents relating to payments or items of value provided to customers. The Company is fully cooperating with this inquiry. Any allegations relating to post-market clinical studies in this matter were resolved as part of the settlement agreement with the U.S. Department of Justice, described in the matter with the U.S. Attorney’s Office for the District of Minnesota above.

On March 12, 2010, the Company received a civil investigative demand from the U.S. Department of Justice pursuant to the federal False Claims Act seeking information regarding the Company’s knowledge about claims to Medicare for the implantation of implantable cardioverter defibrillators (ICDs), including reimbursement advice given by the Company, payments to persons or entities involved in decisions about implantation of ICDs, and the national coverage determination relating to ICDs. The Company is fully cooperating with this investigation.

On October 14, 2010, the Company received a subpoena issued by the United States Attorney’s Office for the Western District of New York pursuant to HIPAA, relating to the Company’s sales, marketing, and reimbursement support practices regarding certain neurostimulation devices. The Company is fully cooperating with this investigation.

On November 9, 2010, the French Competition Authority commenced an investigation of the Company, along with a number of other medical device companies, and the companies’ trade association, Syndicat National de l’Industrie des Technologies Medicales (SNITEM), to determine whether such companies or SNITEM engaged in any anticompetitive practices in responding to tenders to purchase certain medical devices. The Company is fully cooperating with the investigation.

On August 24, 2011, the Company received a letter from the United States Department of Justice requesting information relating to the Company’s practices regarding the replacement of insulin pumps for Medicare beneficiaries. The Company is fully cooperating with this inquiry.

With the exception of the $24 million in expense that was recorded in fiscal year 2011 relating to the investigation by the U.S. Attorney’s Office for the District of Minnesota described above, the Company has not recorded an expense related to losses in connection with these matters because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters.

In the normal course of business, the Company periodically enters into agreements that require it to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising out of the Company’s products or the negligence of its personnel or claims alleging that its products infringe third-party patents or other intellectual property. The Company’s maximum exposure under these indemnification provisions cannot be estimated, and the Company has not accrued any liabilities within the consolidated financial statements. Historically, the Company has not experienced significant losses on these types of indemnifications.

Note 20 – Segment and Geographic Information

Segment information

The Company’s Cardiac and Vascular Group consists of three businesses: Cardiac Rhythm Disease Management (CRDM), CardioVascular, and Physio-Control. The primary products sold by this operating segment include those for cardiac rhythm disorders, cardiovascular disease, and external defibrillation. The Company’s Restorative Therapies Group consists of four businesses: Spinal, Neuromodulation, Diabetes, and Surgical Technologies. The primary products sold by this operating segment include those for spinal conditions and musculoskeletal trauma, neurological disorders, urological and digestive disorders, diabetes, and ear, nose, and throat conditions.

The Company’s management evaluates performance and allocates resources based on profit and loss from operations before income taxes and interest expense, net, not including special charges, restructuring charges, certain litigation charges, net, acquisition-related items, and certain tax adjustments. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in the Company’s Annual Report on Form 10-K for the year ended April 29, 2011.

30


Table of Contents


MEDTRONIC, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Net sales of the Company’s reportable segments include end-customer revenues from the sale of products they each develop and manufacture or distribute. Net sales and earnings before income taxes by reportable segment are as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

Six months ended

 

(in millions)

 

October 28,
2011

 

October 29,
2010

 

October 28,
2011

 

October 29,
2010

 

Cardiac and Vascular Group

 

$

2,207

 

$

2,095

 

$

4,413

 

$

4,122

 

Restorative Therapies Group

 

 

1,925

 

 

1,808

 

 

3,768

 

 

3,555

 

Total Net Sales

 

$

4,132

 

$

3,903

 

$

8,181

 

$

7,677 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

Six months ended

 

(in millions)

 

October 28,
2011

 

October 29,
2010

 

October 28,
2011

 

October 29,
2010

 

Cardiac and Vascular Group

 

$

657

 

$

710

 

$

1,376

 

$

1,427

 

Restorative Therapies Group

 

 

481

 

 

500

 

 

971

 

 

988

 

Total Reportable Segments’ Earnings Before Income Taxes

 

 

1,138

 

 

1,210

 

 

2,347

 

 

2,415

 

Certain litigation charges, net

 

 

 

 

(279

)

 

 

 

(279

)

Acquisition-related items

 

 

17

 

 

(24

)

 

4

 

 

(39

)

Interest expense, net

 

 

(38

)

 

(67

)

 

(70

)

 

(141

)

Corporate

 

 

(64

)

 

(88

)

 

(206

)

 

(164

)

Total Earnings Before Income Taxes

 

$

1,053

 

$

752

 

$

2,075

 

$

1,792

 

The following table presents the Company’s net assets by reportable segment:

 

 

 

 

 

 

 

 

(in millions)

 

October 28,
2011

 

April 29,
2011

 

Cardiac and Vascular Group

 

$

7,078

 

$

6,774

 

Restorative Therapies Group

 

 

10,998

 

 

10,539

 

Total Net Assets of Reportable Segments

 

 

18,076

 

 

17,313

 

Short-term borrowings

 

 

(2,050

)

 

(1,723

)

Long-term debt

 

 

(8,222

)

 

(8,112

)

Corporate

 

 

8,935

 

 

8,490

 

Total Net Assets

 

$

16,739

 

$

15,968

 


Geographic information

Net sales to external customers by geography are as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

Six months ended

 

(in millions)

 

October 28,
2011

 

October 29,
2010

 

October 28,
2011

 

October 29,
2010

 

United States

 

$

2,300

 

$

2,295

 

$

4,506

 

$

4,524

 

Europe and Central Asia

 

 

976

 

 

865

 

 

1,985

 

 

1,727

 

Asia Pacific

 

 

612

 

 

520

 

 

1,205

 

 

1,006

 

Other Foreign

 

 

244

 

 

223

 

 

485

 

 

420

 

Total Net Sales

 

$

4,132

 

$

3,903

 

$

8,181

 

$

7,677

 

Note 21 – Subsequent Events

On November 16, 2011, the Company and Bain Capital entered into a definitive agreement under which affiliates of Bain Capital will acquire Physio-Control and related entities for cash in a transaction valued at approximately $404 million excluding closing adjustments and potential earn-outs. Subsequent to the fiscal year 2012 second quarter, the $210 million net assets of Physio-Control to be sold met the accounting criteria to be classified as held for sale and will be aggregated and reported in accordance with authoritative guidance in the Company’s fiscal year 2012 third quarter Form 10-Q. The transaction is expected to close in the first quarter of calendar 2012, and is subject to certain regulatory and customary closing conditions.

31


Table of Contents


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

UNDERSTANDING OUR FINANCIAL INFORMATION

The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of Medtronic, Inc. and its subsidiaries (Medtronic or the Company). For a full understanding of financial condition and results of operations, you should read this discussion along with management’s discussion and analysis of financial condition and results of operations in our Annual Report on Form 10-K for the year ended April 29, 2011. In addition, you should read this discussion along with our condensed consolidated financial statements and related Notes thereto as of October 28, 2011.

Financial Trends

Throughout this management’s discussion and analysis, you will read about transactions or events that materially contribute to or reduce earnings and materially affect financial trends. We refer to these transactions and events as special charges (such as asset impairment or contributions to The Medtronic Foundation), restructuring charges, certain litigation charges, net, acquisition-related items, or certain tax adjustments. These charges, or benefits, result from facts and circumstances that vary in frequency and/or impact to operations. While understanding these charges or benefits is important to understanding and evaluating financial trends, other transactions or events may also have a material impact on financial trends. A complete understanding of the special charges, restructuring charges, certain litigation charges, net, acquisition-related items, and certain tax adjustments is necessary in order to estimate the likelihood that financial trends will continue.

EXECUTIVE LEVEL OVERVIEW

We are the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world. We develop, manufacture, and market our medical devices in more than 120 countries. Our primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes, and ear, nose, and throat conditions.

We operate under two reportable segments and two operating segments, the Cardiac and Vascular Group (composed of the Cardiac Rhythm Disease Management (CRDM), CardioVascular, and Physio-Control businesses) and the Restorative Therapies Group (composed of the Spinal, Neuromodulation, Diabetes, and Surgical Technologies businesses).

Net earnings for the second quarter of fiscal year 2012 were $871 million, or $0.82 per diluted share, as compared to net earnings of $566 million, or $0.52 per diluted share for the same period in the prior fiscal year, representing an increase of 54 percent and 58 percent, respectively. Net earnings for the three months ended October 28, 2011 included after-tax acquisition-related items, net that increased net earnings by $19 million ($17 million pre-tax). Net earnings for the three months ended October 29, 2010 included after-tax acquisition-related items, net and certain litigation charges, net that decreased net earnings by $294 million ($303 million pre-tax). See further discussion of these items in the “Certain Litigation Charges, Net, Acquisition-Related Items, and Restructuring Charges” section of this management’s discussion and analysis.

Net earnings for the six months ended October 28, 2011 were $1.692 billion, or $1.59 per diluted share, as compared to net earnings of $1.396 billion, or $1.28 per diluted share for the same period in the prior fiscal year, representing an increase of 21 percent and 24 percent, respectively. Net earnings for the six months ended October 28, 2011 included after-tax acquisition-related items, net that increased net earnings by $8 million ($4 million pre-tax). Net earnings for the six months ended October 29, 2010 included after-tax acquisition-related items, net and certain litigation charges, net that decreased net earnings by $305 million ($318 million pre-tax). See further discussion of these items in the “Certain Litigation Charges, Net, Acquisition-Related Items, and Restructuring Charges” section of this management’s discussion and analysis.

The table below illustrates net sales by operating segment for the three and six months ended October 28, 2011 and October 29, 2010:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

 

 

 

Six months ended

 

 

 

 

(dollars in millions)

 

October 28,
2011

 

October 29,
2010

 

% Change

 

 

October 28,
2011

 

October 29,
2010

 

% Change

 

Cardiac and Vascular Group

 

$

2,207

 

$

2,095

 

 

5

%

 

$

4,413

 

$

4,122

 

 

7

%

Restorative Therapies Group

 

 

1,925

 

 

1,808

 

 

6

 

 

 

3,768

 

 

3,555

 

 

6

 

Total Net Sales

 

$

4,132

 

$

3,903

 

 

6

%

 

$

8,181

 

$

7,677

 

 

7

%

32


Table of Contents


Net sales for the three and six months ended October 28, 2011 were $4.132 billion and $8.181 billion, an increase of 6 percent and 7 percent, respectively, from the same periods in the prior fiscal year. Foreign currency translation had a favorable impact of $123 million and $309 million on net sales for the three and six months ended October 28, 2011, respectively, when compared to the same periods in the prior fiscal year. The net sales increase for the three and six months ended October 28, 2011 was driven by an increase of 5 percent and 7 percent, respectively, in our Cardiac and Vascular Group and an increase of 6 percent for both periods in our Restorative Therapies Group. The Cardiac and Vascular Group’s growth for the three and six months ended October 28, 2011 was due to an increase in net sales in Coronary, Structural Heart, Endovascular and Peripheral, CRDM pacing systems, and Atrial Fibrillation (AF) Solutions, partially offset by declines in CRDM defibrillation systems. Our Restorative Therapies Group’s growth for the three and six months ended October 28, 2011 was due to strong net sales in the Diabetes and Surgical Technologies businesses, as well as growth in Neuromodulation, partially offset by weaker net sales in Spinal. See our discussion in the “Net Sales” section of this management’s discussion and analysis for more information on the results of our significant operating segments.

We remain committed to our Mission of developing lifesaving and life-enhancing therapies to alleviate pain, restore health, and extend life. The diversity and depth of our current product offerings enable us to provide medical therapies to patients worldwide. We work to improve patient access through well-planned studies which show the safety, efficacy, and cost-effectiveness of our therapies, and our alliances with patients, clinicians, regulators, and reimbursement agencies. Our investments in research and development, strategic acquisitions, expanded clinical trials, and infrastructure provide the foundation for our growth. We are confident in our ability to drive long-term shareholder value using principles of our Mission, our strong product pipelines, and our continued commitment to innovative research and development.

CRITICAL ACCOUNTING ESTIMATES

We have adopted various accounting policies to prepare the condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP). Our most significant accounting policies are disclosed in Note 1 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended April 29, 2011.

The preparation of the condensed consolidated financial statements, in conformity with U.S. GAAP, requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying Notes. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, asset impairment, legal proceedings, in-process research and development (IPR&D), contingent consideration, warranty obligations, product liability, self-insurance, pension and post-retirement obligations, sales returns and discounts, stock-based compensation, valuation of equity and debt securities, and income tax reserves are updated as appropriate, which in most cases is quarterly. We base our estimates on historical experience, actuarial valuations, or various assumptions that are believed to be reasonable under the circumstances.

Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made, and (2) material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:

Legal Proceedings

We are involved in a number of legal actions involving both product liability and intellectual property disputes. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief (including injunctions barring the sale of products that are the subject of the lawsuit), that could require significant expenditures or result in lost revenues. In accordance with U.S. GAAP, we record a liability in our condensed consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the condensed consolidated financial statements. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded. Estimates of probable losses resulting from litigation and governmental matters are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery; involve unsubstantiated or indeterminate claims for damages; potentially involve penalties, fines, or punitive damages; or could result in a change in business practice. Our significant legal proceedings are discussed in Note 19 to the condensed consolidated financial statements. While it is not possible to predict the outcome for most of the matters discussed in Note 19 to the condensed consolidated financial statements, we believe it is possible that costs associated with them could have a material adverse impact on our consolidated earnings, financial position, or cash flows.

33


Table of Contents


Tax Strategies

Our effective tax rate is based on income, statutory tax rates, and tax planning opportunities available to us in the various jurisdictions in which we operate. We establish reserves when, despite our belief that our tax return positions are fully supportable, we believe that certain positions are likely to be challenged and that we may or may not prevail. These reserves are established and adjusted in accordance with the principles of U.S. GAAP. Under U.S. GAAP, if we determine that a tax position is more likely than not of being sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50 percent likely of being realized upon settlement. We presume that all tax positions will be examined by a taxing authority with full knowledge of all relevant information. We regularly monitor our tax positions and tax liabilities. We reevaluate the technical merits of our tax positions and recognize an uncertain tax benefit, or derecognize a previously recorded tax benefit, when (i) there is a completion of a tax audit, (ii) there is a change in applicable tax law including a tax case or legislative guidance, or (iii) there is an expiration of the statute of limitations. Significant judgment is required in accounting for tax reserves. Although we believe that we have adequately provided for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on our effective tax rate in future periods.

In the event there is a special or restructuring charge, certain litigation charge, net, and/or acquisition-related items recognized in our operating results, the tax cost or benefit attributable to that item is separately calculated and recorded. Because the effective rate can be significantly impacted by these discrete items that take place in the period, we often refer to our tax rate using both the effective rate and the non-GAAP nominal tax rate. The non-GAAP nominal tax rate is defined as the income tax provision as a percentage of earnings before income taxes, excluding special and restructuring charges, certain litigation charges, net, acquisition-related items, and certain tax adjustments. We believe this resulting non-GAAP financial measure provides useful information to investors because it excludes the effect of these discrete items so that investors can compare our recurring results over multiple periods. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP financial measure may not be the same as similar measures presented by other companies.

Tax regulations require certain items to be included in the tax return at different times than when those items are required to be recorded in the condensed consolidated financial statements. As a result, our effective tax rate reflected in our condensed consolidated financial statements is different than that reported in our tax returns. Some of these differences are permanent, such as expenses that are not deductible on our tax return, and some are temporary differences, such as depreciation expense. Temporary differences create deferred tax assets and liabilities. Deferred tax assets generally represent items that can be used as a tax deduction or credit in our tax return in future years for which we have already recorded the tax benefit in our condensed consolidated statements of earnings. We establish valuation allowances for our deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense recognized in our condensed consolidated financial statements for which payment has been deferred or expense has already been taken as a deduction on our tax return but has not yet been recognized as an expense in our condensed consolidated statements of earnings.

The Company’s overall tax rate including the tax impact of acquisition-related items has resulted in an effective tax rate of 17.28 and 18.46 percent for the three and six months ended October 28, 2011, respectively. Excluding the impact of acquisition-related items in the three and six months ended October 28, 2011, our operational and tax strategies have resulted in a non-GAAP nominal tax rate of 17.90 and 18.73 percent, respectively, versus the U.S. Federal statutory rate of 35.0 percent. An increase in our nominal tax rate of 1 percent would result in an additional income tax provision for the three and six months ended October 28, 2011 of approximately $10 million and $21 million, respectively. See discussion of the tax rate and the tax adjustments in the “Income Taxes” section of this management’s discussion and analysis.

Valuation of IPR&D, Contingent Consideration, Goodwill, and Other Intangible Assets

When we acquire a business, the purchase price is allocated, as applicable, among IPR&D, other identifiable intangible assets, net tangible assets, and goodwill as required by U.S. GAAP. IPR&D is defined as the value assigned to those projects for which the related products have not received regulatory approval and have no alternative future use. Determining the portion of the purchase price allocated to IPR&D and other intangible assets requires us to make significant estimates. The amount of the purchase price allocated to IPR&D and other intangible assets is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of the acquisition in accordance with accepted valuation methods. For IPR&D, these valuation methodologies include consideration of the risk of the project not achieving commercial feasibility.

Contingent consideration is recorded at the estimated fair value of the contingent consideration milestone payments on the acquisition date for all acquisitions subsequent to April 24, 2009. The acquisition date fair value is measured based on the consideration expected to be transferred (probability-weighted), discounted back to present value. The discount rate used is determined at the time of the acquisition in accordance with accepted valuation methods. The fair value of the contingent milestone consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recorded as income or expense in the acquisition-related items within our condensed consolidated statements of earnings.

Goodwill represents the excess of the aggregate purchase price over the fair value of net assets, including IPR&D, of acquired businesses. Goodwill is tested for impairment annually or more frequently if changes in circumstance or the occurrence of triggering events suggest that the carrying amount may be impaired.

34


Table of Contents


The test for impairment requires us to make several estimates about fair value, most of which are based on projected future cash flows. Our estimates associated with the goodwill impairment tests are considered critical due to the amount of goodwill recorded on our condensed consolidated balance sheets and the judgment required in determining fair value, including projected future cash flows. Goodwill was $9.944 billion and $9.537 billion as of October 28, 2011 and April 29, 2011, respectively.

Other intangible assets include patents, trademarks, purchased technology, and IPR&D. Intangible assets with a definite life are amortized on a straight-line or accelerated basis, as appropriate, with estimated useful lives ranging from three to 20 years. We review all intangible assets for impairment annually or as changes in circumstances or the occurrence of events suggest the remaining value may not be recoverable. Other intangible assets, net of accumulated amortization, were $2.875 billion and $2.777 billion as of October 28, 2011 and April 29, 2011, respectively.

NEW ACCOUNTING PRONOUNCEMENTS

Information regarding new accounting pronouncements is included in Note 2 to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q.

ACQUISITIONS

Three and six months ended October 28, 2011

On August 31, 2011, we acquired Salient Surgical Technologies, Inc. (Salient). Salient develops and markets devices for haemostatic sealing of soft tissue and bone incorporating advanced energy technology. Salient’s devices are used in a variety of surgical procedures including orthopedic surgery, spine, open abdominal, and thoracic procedures. Total consideration for the transaction was approximately $497 million. We had previously invested in Salient and held an 8.9 percent ownership position in the company. In connection with the acquisition of Salient, we recognized a gain on our previously held investment of $32 million, which was recorded within acquisition-related items in the condensed consolidated statement of earnings in the second quarter of fiscal year 2012. Net of this ownership position, the transaction value was approximately $452 million.

On August 31, 2011, we acquired PEAK Surgical, Inc. (PEAK). PEAK develops and markets tissue dissection devices incorporating advanced energy technology. Total consideration for the transaction was approximately $113 million. We had previously invested in PEAK and held an 18.9 percent ownership position in the company. In connection with the acquisition of PEAK, we recognized a gain on our previously held investment of $6 million, which was recorded within acquisition-related items in the condensed consolidated statement of earnings in the second quarter of fiscal year 2012. Net of this ownership position, the transaction value was approximately $96 million.

Three and six months ended October 29, 2010

On September 14, 2010, we acquired a developer of vascular suturing products used in connection with cardiovascular and vascular procedures that require a puncture or incision to the artery. Total consideration for the transaction was valued at approximately $21 million.

On August 12, 2010, we acquired ATS Medical, Inc. (ATS Medical). ATS Medical is a leading developer, manufacturer, and marketer of products and services focused on cardiac surgery, including heart valves and surgical cryoablation technology. Under the terms of the agreement, ATS Medical shareholders received $4.00 per share in cash for each share of ATS Medical common stock that they owned. Total consideration for the transaction was $394 million which includes the assumption of existing ATS Medical debt and acquired contingent consideration.

On June 2, 2010, we acquired substantially all of the assets of Axon Surgical (Axon), a privately held company. Prior to the acquisition, we distributed a large portion of Axon’s products. We believe this acquisition will allow us to bring to market the next generation of surgeon-directed and professionally supported spinal neuromonitoring technology and expand the availability of this technology. Total consideration for the transaction, net of cash acquired, was $62 million, which includes the settlement of existing Axon debt.

The pro forma impact of the above acquisitions was not significant, individually or in the aggregate, to our results for the three and six months ended October 28, 2011.

In addition to the acquisitions above, we periodically acquire certain tangible or intangible assets from enterprises that do not otherwise qualify for accounting as a business combination. These transactions are largely reflected in the condensed consolidated statements of cash flows as a component of investing activities under purchase of intellectual property.

35


Table of Contents


NET SALES

The table below illustrates net sales by product line and operating segment for the three and six months ended October 28, 2011 and October 29, 2010:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

 

 

Six months ended

 

 

 

 

(dollars in millions)

 

October 28,
2011

 

October 29,
2010

 

% Change

 

October 28,
2011

 

October 29,
2010

 

% Change

 

Defibrillation Systems

 

$

708

 

$

745

 

 

(5

)%

$

1,405

 

$

1,467

 

 

(4

)%

Pacing Systems

 

 

511

 

 

472

 

 

8

 

 

1,019

 

 

945

 

 

8

 

AF and Other

 

 

49

 

 

31

 

 

58

 

 

97

 

 

62

 

 

56

 

CARDIAC RHYTHM DISEASE MANAGEMENT

 

 

1,268

 

 

1,248

 

 

2

 

 

2,521

 

 

2,474

 

 

2

 

Coronary

 

 

376

 

 

350

 

 

7

 

 

766

 

 

692

 

 

11

 

Structural Heart

 

 

266

 

 

237

 

 

12

 

 

541

 

 

461

 

 

17

 

Endovascular and Peripheral

 

 

188

 

 

151

 

 

25

 

 

374

 

 

302

 

 

24

 

CARDIOVASCULAR

 

 

830

 

 

738

 

 

12

 

 

1,681

 

 

1,455

 

 

16

 

PHYSIO-CONTROL

 

 

109

 

 

109

 

 

 

 

211

 

 

193

 

 

9

 

TOTAL CARDIAC AND VASCULAR GROUP

 

 

2,207

 

 

2,095

 

 

5

 

 

4,413

 

 

4,122

 

 

7

 

Core Spinal

 

 

631

 

 

634

 

 

 

 

1,240

 

 

1,257

 

 

(1

)

Biologics

 

 

208

 

 

216

 

 

(4

)

 

423

 

 

423

 

 

 

SPINAL

 

 

839

 

 

850

 

 

(1

)

 

1,663

 

 

1,680

 

 

(1

)

NEUROMODULATION

 

 

421

 

 

388

 

 

9

 

 

818

 

 

758

 

 

8

 

DIABETES

 

 

367

 

 

326

 

 

13

 

 

722

 

 

638

 

 

13

 

SURGICAL TECHNOLOGIES

 

 

298

 

 

244

 

 

22

 

 

565

 

 

479

 

 

18

 

TOTAL RESTORATIVE THERAPIES GROUP

 

 

1,925

 

 

1,808

 

 

6

 

 

3,768

 

 

3,555

 

 

6

 

TOTAL

 

$

4,132

 

$

3,903

 

 

6

%

$

8,181

 

$

7,677

 

 

7

%

Net sales for the three and six months ended October 28, 2011 were favorably impacted by foreign currency translation of $123 million and $309 million, respectively, when compared to the same periods of the prior fiscal year. The primary exchange rate movements that impacted our consolidated net sales growth were the U.S. dollar as compared to the Euro and the Japanese Yen. The impact of foreign currency fluctuations on net sales was not indicative of the impact on net earnings due to the offsetting foreign currency impact on operating costs and expenses and our hedging activities. See “Item 3 – Quantitative and Qualitative Disclosures About Market Risk” and Note 9 to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q for further details on currency exchange rate derivative instruments and our related risk management strategies.

Cardiac and Vascular Group

The Cardiac and Vascular Group is composed of the CRDM, CardioVascular, and Physio-Control businesses. The Cardiac and Vascular Group’s products include pacemakers, implantable defibrillators, leads and delivery systems, ablation products, electrophysiology catheters, products for the treatment of atrial fibrillation, information systems for the management of patients with CRDM devices, coronary and peripheral stents and related delivery systems, therapies for uncontrolled hypertension, endovascular stent graft systems, heart valve replacement technologies, tissue ablation systems, open heart and coronary bypass grafting surgical products, external defibrillators including manual defibrillator/monitors used by hospitals and emergency response personnel, and automated external defibrillators used in commercial and public settings for the treatment of cardiac arrest. The Cardiac and Vascular Group’s net sales for the three and six months ended October 28, 2011 were $2.207 billion and $4.413 billion, an increase of 5 percent and 7 percent, respectively, over the same periods in the prior fiscal year. Foreign currency translation had a favorable impact on net sales for the three and six months ended October 28, 2011 of approximately $81 million and $203 million, respectively, when compared to the same periods in the prior fiscal year. The Cardiac and Vascular Group’s growth for the three and six months ended October 28, 2011 was a result of strong sales in Coronary, Structural Heart, Endovascular and Peripheral, CRDM pacing systems, and AF Solutions, partially offset by a decline in CRDM defibrillation systems. Additionally, for the three months ended October 28, 2011, Physio-Control’s net sales growth was flat, but for the six months ended October 28, 2011, Physio-Control’s net sales growth positively impacted the overall performance of the Cardiac and Vascular Group. Cardiac and Vascular Group’s performance was impacted by new products, the continued macroeconomic downturn, pricing pressures due to competition, slowing of certain market growth rates, the implantable cardioverter defibrillator (ICD) utilization article in the January 2011 Journal of the American Medical Association, the hospital investigation by the U.S. Department of Justice, and the continued trend of increased hospital ownership of physician practices. See the more detailed discussion of each business’s performance below.

36


Table of Contents


CRDM net sales for the three and six months ended October 28, 2011 were $1.268 billion and $2.521 billion, an increase of 2 percent for both periods when compared to the same periods in the prior fiscal year. Net sales of our defibrillation system products for the three and six months ended October 28, 2011 declined primarily due to the continued decline in the U.S. market, which affected procedure volumes and pricing. The U.S. market was impacted by a number of factors, such as the ICD utilization article in the January 2011 Journal of the American Medical Association, the hospital utilization investigation by the U.S. Department of Justice, and the continued trend of increased hospital ownership of physician practices. The decline in net sales of our defibrillation system products was partially offset by net sales growth from the Protecta SmartShock (Protecta) family of devices, which were launched in the U.S. during the fourth quarter of fiscal year 2011. Net sales of our pacing system products for the three and six months ended October 28, 2011 increased primarily due to growth in the U.S. for the Revo Magnetic Resonance Imaging (MRI) SureScan pacing system, which was launched in the fourth quarter of fiscal year 2011. Additionally, worldwide net sales of our AF Solutions products for the three and six months ended October 28, 2011 increased primarily due to the continued acceptance in the U.S. and in certain international markets of the Arctic Front Cardiac CryoAblation Catheter system (Arctic Front system), which was launched in the U.S. in the third quarter of fiscal year 2011.

CardioVascular net sales for the three and six months ended October 28, 2011 were $830 million and $1.681 billion, an increase of 12 percent and 16 percent, respectively, over the same periods in the prior fiscal year. The increase in CardioVascular net sales for the three and six months ended October 28, 2011 was primarily due to growth outside the U.S. in our Coronary, Structural Heart, and Endovascular and Peripheral businesses. The primary contributors to net sales growth were driven by the Resolute Integrity drug-eluting stent outside the U.S. and our Integrity bare metal stent within Coronary, the Endurant Abdominal and Valiant Captivia Thoracic Stent Graft Systems within Endovascular, and the continued acceptance outside the U.S. of our transcatheter valves within Structural Heart. Additionally, for the three months ended October 28, 2011, the January 2011 acquisition of Ardian, Inc. (Ardian), and for the six months ended October 28, 2011, the acquisitions of ATS Medical and Ardian, contributed to the overall growth in net sales of the CardioVascular business.

Physio-Control net sales for the three and six months ended October 28, 2011 were $109 million and $211 million, flat and an increase of 9 percent, respectively, over the same periods in the prior fiscal year. Physio-Control’s growth rate performance for the three months ended October 28, 2011 was negatively impacted by the resumption in the second quarter of the prior fiscal year following the resolution of a supply constraint issue. The increase in net sales growth for the six months ended October 28, 2011 was driven by strong growth in the LIFEPAK 15 and LUCAS chest compression system products.

Looking ahead, we expect our Cardiac and Vascular Group could be impacted by the following:

 

 

 

 

The slowdown in certain market growth rates. Our performance in the Cardiac and Vascular Group has been and will continue to be affected by continued market growth and our ability to increase or maintain our market position. The current Cardiac and Vascular Group market is impacted by increasing pricing pressures, competition, and slowing procedure growth.

 

 

 

 

The recent slowdown in market growth rates for our U.S. defibrillation system products. We believe the U.S. market could continue to be impacted during fiscal year 2012 by the ICD utilization article in the January 2011 Journal of the American Medical Association, the hospital utilization investigation by the U.S. Department of Justice, and the continued trend of increased hospital ownership of physician practices.

 

 

 

 

Continued market acceptance of our Protecta family of devices which was launched in the U.S. in the fourth quarter of fiscal year 2011. The Protecta portfolio leverages the already established Vision 3D platform to deliver a full suite of single, dual, and triple chamber defibrillators that include SmartShock Technology, a family of new Medtronic-exclusive algorithms that reduces the delivery of inappropriate shocks, which is a leading clinical request from physicians.

 

 

 

 

Continued and future growth of the first pacing system developed specifically for use in MRI machines. During the fourth quarter of fiscal year 2010 we launched Advisa MRI SureScan, our next generation MRI pacing system in Europe and, early in the fourth quarter of fiscal year 2011, we received U.S. Food and Drug Administration (FDA) approval for the Revo MRI SureScan, our first generation MRI pacing system in the U.S. Both Advisa MRI SureScan and Revo MRI SureScan are designed to address and mitigate interactions between the pacing system and the magnetic resonance imaging environment. We believe that these MRI compatible products will help drive potential share gains and alleviate pricing pressures.

 

 

 

 

Continued and future growth from the launch of the Arctic Front system in the U.S. The Arctic Front system is a cryoballoon indicated for the treatment of drug refractory paroxysmal atrial fibrillation. The cryoballoon treatment involves a minimally invasive procedure that efficiently creates circumferential lesions around the pulmonary vein, which is the source of erratic electrical signals that cause irregular heartbeat.

 

 

 

 

Continued acceptance of the Resolute drug eluting stent in markets outside the U.S.

37


Table of Contents



 

 

 

 

Continued and future acceptance of the new Integrity bare metal stent and Resolute Integrity drug eluting coronary stent in certain international markets. The Integrity platform features a laser-fused sinusoidal technology that is designed to significantly improve flexibility and conformability compared to the Driver stent and other technologies. The Resolute Integrity drug eluting coronary stent was launched in Europe in August 2010. While the global stent market continues to experience year-over-year declines, to date we have been successful in gaining share with this stent platform in those geographies where the product has been approved. Additionally, we expect to launch the Resolute Integrity drug eluting coronary stent in the U.S. towards the end of fiscal year 2012.

 

 

 

 

Continued integration of Ardian, which was acquired in January 2011. Ardian develops catheter-based therapies to treat uncontrolled hypertension and related conditions. Ardian’s Symplicity Catheter System addresses uncontrolled hypertension through renal denervation, or ablation of the nerves lining the renal arteries. It has received Conformité Européene (CE) Mark and Australia’s Therapeutic Goods Administration listing. We believe this acquisition offers the opportunity to lead the development of renal denervation, augments our existing interventional therapies, and complements our catheter design and ablation technologies.

 

 

 

 

Growth in the U.S. from the launch of the Endurant Abdominal Stent Graft System, which was approved and launched in the third quarter of fiscal year 2011. Results to date indicate strong market acceptance.

 

 

 

 

Further and future growth in the U.S. and Japan from the Talent Thoracic Stent Graft System. In the U.S., the Talent Thoracic Stent Graft System, on an improved delivery system, Captivia, was launched in the third quarter of fiscal year 2011. In addition, our Talent Abdominal Aortic Aneurysm Stent Graft System and improved delivery system, Xcelerant, for our Thoracic Stent Graft System was approved in Japan in the third quarter of fiscal year 2011.

 

 

 

 

Sales growth outside the U.S. with continued acceptance of our next generation Endurant Abdominal Stent Graft System and our Valiant Captivia Thoracic Stent Graft System.

 

 

 

 

Continued acceptance of our CoreValve transcatheter heart valve technologies for the replacement of the aortic valve. CoreValve’s Percutaneous Revalving System has received CE Mark approval and is currently available outside the U.S. The CoreValve 31millimeter received CE Mark approval in the first quarter of fiscal year 2012 and we continue to expect CE Mark approval for our CoreValve 23 millimeter system in the second half of fiscal year 2012. Additionally, we continue to make progress on the CoreValve U.S. pivotal study; we expect to finish enrollment in the extreme risk arm by the end of the calendar year and the high risk arm by next summer. Also, we started our CoreValve pivotal trial in Japan during November 2011.

 

 

 

 

The divestiture of Physio-Control. On November 16, 2011, we entered into a definitive agreement with Bain Capital under which affiliates of Bain Capital will acquire Physio-Control and related entities for cash in a transaction valued at approximately $404 million excluding closing adjustments and potential earn-outs. The transaction is expected to close in the first quarter of calendar 2012, and is subject to certain regulatory and customary closing conditions.

Restorative Therapies Group

The Restorative Therapies Group is composed of the Spinal, Neuromodulation, Diabetes, and Surgical Technologies businesses. Products in the Restorative Therapies Group include products for various areas of the spine, bone graft substitutes, biologic products, implantable neurostimulation therapies and drug delivery devices for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder (OCD), overactive bladder, urinary retention, fecal incontinence and gastroparesis, external insulin pumps, subcutaneous continuous glucose monitoring (CGM) systems, products to treat conditions of the ear, nose, and throat, and advanced energy products. Additionally, this group manufactures and sells primarily image-guided surgery and intra-operative imaging systems. The Restorative Therapies Group’s net sales for the three and six months ended October 28, 2011 were $1.925 billion and $3.768 billion, an increase of 6 percent for both periods when compared to the same periods in the prior fiscal year. Foreign currency translation had a favorable impact on net sales for the three and six months ended October 28, 2011 of approximately $42 million and $106 million, respectively, when compared to the same periods in the prior fiscal year. The Restorative Therapies Group’s growth for the three and six months ended October 28, 2011 was primarily a result of strong net sales in Diabetes and Surgical Technologies, as well as growth in Neuromodulation, partially offset by weaker net sales in Spinal. The Restorative Therapies Group’s performance was impacted by the recent launch of notable products, sales force expansion, the acquisitions of Salient and PEAK (not part of Surgical Technologies during the second quarter of fiscal year 2011), the continued macroeconomic downturn, continued increased payor scrutiny, competition, and the continued trend of increased hospital ownership of physician practices. See the more detailed discussion of each business’s performance below.

38


Table of Contents


Spinal net sales for the three and six months ended October 28, 2011 were $839 million and $1.663 billion, a decrease of 1 percent for both periods when compared to the same periods in the prior fiscal year. Spinal’s performance for the three and six months ended October 28, 2011 was negatively impacted by the decline in sales of INFUSE Bone Graft, which declined 15 percent and 11 percent, respectively, and Kyphon Balloon Kyphoplasty (BKP), which declined 6 percent and 8 percent, respectively, over the same periods in the prior fiscal year. The decline in INFUSE Bone Graft sales was primarily driven by the June 2011 articles in The Spine Journal as further described below. The decline in BKP sales was due to the continued decrease in demand and competitive pricing pressures. Additionally, Spinal net sales for the three and six months ended October 28, 2011 were negatively impacted by a decrease in the number of Spinal procedures as certain patients are postponing elective procedures due to current macroeconomic and other factors, continued pricing pressures, and a challenging reimbursement environment in many of our major markets. Spinal’s negative performance was partially offset by growth from the ongoing launch of new product lines, including Solera, Vertex Select, and Atlantis Vision Elite cervical plates and from our acquisition of Osteotech, Inc. (Osteotech) during the third quarter of fiscal year 2011. Additionally, Spinal net sales were positively impacted by growth outside the U.S. including the benefit from the joint venture with Shandong Weigao Group Medical Polymer Company Limited (Weigao). The joint venture distributes Medtronic’s spinal products in the premium segment and Weigao’s spinal and orthopedic products in the value and economic segment in China.

Neuromodulation net sales for the three and six months ended October 28, 2011 were $421 million and $818 million, an increase of 9 percent and 8 percent, respectively, over the same periods in the prior fiscal year. The increase in net sales for the three and six months ended October 28, 2011 was primarily due to the growth of Activa PC and RC deep brain stimulation (DBS) systems for movement disorders, InterStim Therapy for overactive bladder, urinary retention, and bowel control, and Synchromed II drug pumps.

Diabetes net sales for the three and six months ended October 28, 2011 were $367 million and $722 million, an increase of 13 percent for both periods when compared to the same periods in the prior fiscal year. The increase in net sales for the three and six months ended October 28, 2011 was led by international sales growth of 23 percent and 26 percent, respectively, over the same periods in the prior fiscal year. For the three and six months ended October 28, 2011 net sales growth was the result of continued demand in certain markets outside the U.S. for our MiniMed Paradigm Veo System (Veo) and our recently launched Enlite sensor. In addition, the MiniMed Revel System (Revel) contributed to the growth in the U.S. market. We also saw a significant increase in CGM sales worldwide.

Surgical Technologies net sales for the three and six months ended October 28, 2011 were $298 million and $565 million, an increase of 22 percent and 18 percent, respectively, over the same periods in the prior fiscal year. The increase in net sales for the three and six months ended October 28, 2011 was driven by strong performance worldwide across the portfolio of ENT, Power Systems, and Navigation product lines, as well as growth across capital equipment, disposables, and service. Additionally, net sales for the three and six months ended October 28, 2011 were positively impacted by the acquisitions of Salient and PEAK that were acquired in the second quarter of fiscal year 2012.

Looking ahead, we expect our Restorative Therapies Group could be impacted by the following:

 

 

 

 

Growth of the various markets and our ability to grow consistently within those markets. Our performance in the Restorative Therapies Group has been and will continue to be affected by continued market growth and our ability to increase or maintain our market position. The current Restorative Therapies Group market is impacted by growth in procedural volumes partially offset by increasing pricing pressures and competition within the Spinal and Neuromodulation businesses.

 

 

 

 

 •

Market acceptance of innovative new products, including the Vertex Select product line, which was launched in the first quarter of fiscal year 2011, and our new Solera product line. During the fourth quarter of fiscal year 2011, we ramped up our launch of the Solera 4.75 system with a full market release. Additionally, in the second quarter of fiscal year 2012 we had a limited launch of Solera Sextant, our minimally invasive product and later this fiscal year we plan to roll out Solera 5.5/6.0 to address the complex/deformity segment, as well as POWEREASE, a powered instrument solution for Solera.

 

 

 

 

 •

Continued acceptance of our BKP technology. We believe worldwide growth continues to be negatively impacted by the vertebroplasty articles in the August 2009 New England Journal of Medicine. In addition, two new competitors entered the U.S. marketplace in fiscal year 2011 and we anticipate additional competitors to enter in the future.

 

 

 

 

 •

Market acceptance of new high pressure BKP balloons and syringes, curettes, and fixation materials in the Spinal business, which were launched in fiscal year 2011. We expect a positive impact over time from the improvement in certain international markets, such as Japan. Market growth potential in Japan will be dependent upon additional investment and development by market participants. We remain focused on generating evidence to support the clinical and economic benefits for BKP. Additionally, we launched the Xpander II balloon late in the first quarter of fiscal year 2012.

 

 

 

39


Table of Contents



 

 

 

 

Expected future growth opportunities in our Biologics business, driven by our acquisition of Osteotech, which closed in the third quarter of fiscal year 2011.

 

 

 

 

We continue to seek the FDA’s approval to market our new bone graft product, AMPLIFY rhBMP-2 Matrix (AMPLIFY) for single-level, posterolateral spinal fusion procedures in patients with degenerative disc disease. In the third quarter of fiscal year 2011, the FDA sent us a letter advising that the FDA was not able to approve AMPLIFY at that time without additional information from us. In a letter dated December 2,2011, the agency upheld its initial decision but invited us to submit further information in support of the application. We remain in active dialogue with the FDA to address its issues and are hopeful that the FDA will ultimately approve AMPLIFY.

 

 

 

 

Sales growth was negatively impacted from the June 2011 articles in The Spine Journal and by inquiries from governmental authorities, relating to our INFUSE Bone Graft product. The Spine Journal articles suggested that some physicians’ peer-reviewed studies may have underreported complications and adverse events associated with INFUSE. These articles did not question the integrity of the data provided by Medtronic to the FDA for product approval or the disclosure of safety issues on the product’s Instructions for Use for approved indications. However, because questions have been raised about the peer-reviewed literature, we announced in August 2011 that we have given a grant to Yale University to oversee two independent, systematic reviews of all INFUSE-related clinical data. We expect results of the reviews to be concluded in the next fiscal year and we will make all of the INFUSE clinical data and results available to medical researchers. INFUSE Bone Graft global net sales have declined approximately 15 percent as reported in the second quarter of fiscal year 2012.

 

 

 

 

Continued and future acceptance of our current indications for Medtronic DBS Therapy for the treatment of movement disorders, Epilepsy (approved in Europe) and OCD. The DBS Therapy portfolio includes Activa PC, our small and advanced primary cell battery, and Activa RC, a rechargeable DBS device. Additionally, Activa SC was approved in the U.S. and Europe in fiscal year 2011.

 

 

 

 

Continued acceptance of InterStim Therapy for the treatment of the symptoms of overactive bladder, urinary retention, and bowel control. InterStim Therapy for Bowel Control is approved in Europe and launched in the U.S. during the first quarter of fiscal year 2012.

 

 

 

 

Future and continued acceptance of the RestoreSensor, which is currently available in certain international markets and was approved by the FDA in the third quarter of fiscal year 2012.

 

 

 

 

Continued acceptance from both physicians and patients of insulin-pump therapy and CGM therapy and continued acceptance and improved reimbursement of CGM technologies. The Veo insulin pump is available in certain international markets and offers low-glucose suspend, which assists in protecting against the risk of hypoglycemia by automatically suspending insulin delivery when glucose falls below a specified threshold set by the user. In addition, the Revel insulin pump is available in the U.S., extending our line of sensor-augmented therapy options available on the market. Additionally, the Enlite sensor was launched in certain international markets in the fourth quarter of fiscal year 2011.

 

 

 

 

Given the elective nature of an insulin pump and CGM for the management of diabetes and the possible high out-of-pocket costs to the customer, macroeconomic pressures could negatively impact the near-term sales growth within the Diabetes business.

 

 

 

 

Integration of Salient into our Surgical Technologies business. Salient was acquired on August 31, 2011. Salient develops and markets devices for haemostatic sealing of soft tissue and bone incorporating advanced energy technology. Salient’s devices are used in a variety of surgical procedures including orthopedic surgery, spine, open abdominal, and thoracic procedures. We believe this acquisition should increase our competitive position in this market.

 

 

 

 

Integration of PEAK into our Surgical Technologies business. PEAK was acquired on August 31, 2011. PEAK develops and markets tissue dissection devices incorporating advanced energy technology. PEAK’s PlasmaBlade tissue dissection device is based on proprietary technology that represents an important advance in radiofrequency surgical technologies. We believe this acquisition should increase our competitive position in this market.

 

 

 

 

Continued acceptance of the Surgical Technologies StealthStation S7 and O-Arm Imaging Systems, especially with Synergy Spine 2.0 and the O-Arm 3.1.2.

 

 

 

 

Market acceptance of the Surgical Technologies NIM 3.0 Nerve Monitoring System.

40


Table of Contents


COSTS AND EXPENSES

The following is a summary of major costs and expenses as a percent of net sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

Six months ended

 

 

 

October 28,
2011 

 

October 29,
2010 

 

October 28,
2011 

 

October 29,
2010 

 

Cost of products sold

 

 

24.5

%

 

24.6

%

 

24.7

%

 

24.2

%

Research and development

 

 

9.2

 

 

9.6

 </